

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 September 2007 (13.09.2007)

PCT

(10) International Publication Number
WO 2007/103740 A2

(51) International Patent Classification:
C12Q 1/70 (2006.01) *C12Q 1/68* (2006.01)

(21) International Application Number:
PCT/US2007/063090

(22) International Filing Date: 1 March 2007 (01.03.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/777,923 1 March 2006 (01.03.2006) US

(71) Applicant (for all designated States except US): **ARK
DIAGNOSTICS** [US/US]; 1190 Bordeaux Drive, Sunny-
vale, CA 94089 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **VALDEZ, Johnny**
[US/US]; 61 Montclair Drive, Fremont, CA 95139 (US).

(74) Agents: **ESKER, Todd** et al.; Morgan Lewis & Bockius
LLP, 2 Palo Alto Square, 3000 El Camino Real, Suite 700,
Palo Alto, CA 94306 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS,
LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ,
NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL,
PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: IMMUNOASSAYS, HAPTENS, IMMUNOGENS AND ANTIBODIES FOR ANTI-HIV THERAPEUTICS

(57) Abstract: This invention provides compounds, methods, immunoassays, and kits relating to active, metabolically sensitive ("met-sensitive") moieties of anti-HIV therapeutics, such as HIV protease inhibitors (PI), HIV nucleoside reverse transcriptase inhibitors (NRTI) and HIV entry inhibitors (EI).



WO 2007/103740 A2

IMMUNOASSAYS, HAPTENS, IMMUNOGENS AND ANTIBODIES FOR ANTI-HIV THERAPEUTICS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to United States Provisional Patent Application
5 Serial No. 60/777,923 filed on March 1, 2006, which is herein incorporated by reference in its entirety for all purposes.

BACKGROUND OF THE INVENTION

[0002] Acquired Immune Deficiency Syndrome (AIDS), the disease associated with infection from human immunodeficiency virus (HIV), is a disease that is pandemic and
10 leaves practically no country in the world unaffected. The Joint United Nations Program on HIV/AIDS, UNAIDS, estimates that by the end of 2003, more than 40 million people will be living with HIV/AIDS. Unless the HIV lifecycle is interrupted by treatment, the virus infection spreads throughout the body and results in the destruction of the body's immune system and, ultimately, death.

15 [0003] While there is no cure for HIV infection, the introduction of antiretroviral drug therapy has resulted in a drastic reduction in the HIV morbidity and mortality rates. These retroviral drugs fall into four categories: non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as nevirapine and efavirenz, protease inhibitors (PIs), such as indinavir and ritonavir, nucleoside reverse transcription inhibitors (NRTIs), such as emtricitabine and
20 zidovudine, and fusion inhibitors, such as enfuvirtide. Combinations of these classes of drugs are prescribed according to the guidelines of highly active antiretroviral therapy (HAART), which seeks to reduce resistance, adverse reactions, and pill burdens, while improving efficacy. In spite of remarkable success with these new therapeutic regimens, not all patients respond optimally to the HIV combination drug therapies. This is due to multiple factors, but
25 one of the most important is interpatient drug variability.

[0004] Levels of antiretroviral drugs in the blood may vary considerably from patient to patient for many reasons (*e.g.* drug-drug interactions in the body, differences in regimen adherence, differences in metabolism, differences in absorption). There is compelling scientific evidence that the concentrations of these anti-HIV therapeutics in the blood must be
30 held in the right ranges in order to maximize their antiretroviral effect. Both variations above

and below these ranges can present serious health risks to the patient. When anti-HIV therapeutic levels are low, replication of the virus is increased, which can lead to destruction of the immune system in the patient as well as development of HIV strains which are resistant to therapeutic treatment. When anti-HIV therapeutic levels are high, deleterious side effects can occur, such as renal problems with indinavir (Dieleman JP, *et al.*, *AIDS* **13**(4):473-478 (1999)), gastrointestinal disturbances with ritonavir (Gatti G, *et al.*, *AIDS* **13**(15):2083-2089 (1999)), hepatotoxicity with nevirapine (Gonzalez de Requena D, *et al.*, *AIDS* **16**(2):290-291 (2002), and CNS problems with efavirenz (Marzolini C, *et al.*, *AIDS* **15**(9):1192-1194 (2001)). While developing a 'magic bullet' drug without side effects remains an ideal objective, a more realistic goal is to utilize existing antiretroviral therapeutics in a more effective way. By ensuring that each patient has the appropriate levels of the anti-HIV therapeutic in his or her blood, the goal of suppressing virus replication with a minimum of side effects would be achieved. Therapeutic drug monitoring (TDM) offers a strategy for achieving this goal and thus improving antiretroviral therapy.

[0005] TDM involves measuring the amount of a particular drug in a blood sample. By frequently sampling the blood of an HIV-infected patient over time, the unique characteristics of the patient's response to anti-HIV therapeutics can be discovered. From this information, an individualized dosage schedule can be constructed which will maintain adequate drug concentrations throughout the dosing interval and avoid the overdosing or underdosing that could result in deleterious side effects.

[0006] Since TDM requires frequent testing, assays with high specificity, small sample volume requirements, reasonable cost, and rapid turnaround time are required. Currently most reports on TDM for PIs and NRTIs have used high performance liquid chromatography (HPLC) and liquid chromatography-tandem mass spectrometry (LC/MS/MS) methods which are slow, labor-intensive, and expensive. Radioimmunoassays (RIA), while more amenable to high-throughput screening than HPLC or LC/MS/MS, suffer from regulatory, safety and waste disposal issues relating to the radioactive isotope label used in the assay. A TDM format that balances high-throughput screening with safety and environmental concerns would be ideal.

[0007] One promising candidate that combines these factors is non-isotopic immunoassays, such as those described in U.S. Pat. No. 3,817,837 (1974), the disclosure of which is incorporated herein by reference. Recently there have been several reports of non-isotopic

immunoassays for PIs comprising PIs with an additional linker attached (Akeb, F. *et al.*, *J Immunol. Methods* **263(1-2)**:1-9 (2002); U.S. Pat. Application Publication Nos: 2003/0124518 and 2003/0100088). These assays detect not only unmetabolized, active anti-HIV therapeutics, but also detect the metabolized, inactive versions as well. Non-isotopic immunoassays for other classes of anti-HIV therapeutics do not currently exist. Their development would represent a significant advance in the art. This and other problems have been solved by the current invention.

[0008] In addition, currently no methods are available to detect only the unmetabolized, active version of the anti-HIV therapeutic and not the metabolized, inactive version. Their development would represent a significant advance in the art. This and other problems have been solved by the current invention.


BRIEF SUMMARY OF THE INVENTION

[0009] The present invention enables the determination of the presence or the concentration of an active anti-HIV therapeutic in a sample. A variety of haptens, hapten-reactive partner conjugates, receptors, methods, and kits are useful in this determination.


[0010] Thus, in a first aspect, the invention provides a method for determining, in a sample from a host, the presence or the concentration of an anti-HIV therapeutic which inhibits HIV propagation. The anti-HIV therapeutic is selected from the group consisting of a HIV protease inhibitor (PI), a nucleoside HIV reverse transcriptase inhibitor (NRTI) and an entry inhibitor (EI). The anti-HIV therapeutic comprises a metabolically-sensitive ("met-sensitive") moiety that is transformed by the host to yield an inactivated metabolic product. The method of this first aspect comprises combining, in a solution, the sample with a receptor specific for the met-sensitive moiety where the receptor does not bind to the inactivated metabolic product, thus yielding a receptor-anti-HIV therapeutic complex. Finally, the method comprises detecting the complex. In an exemplary embodiment, the method determines only the presence or the concentration of active anti-HIV therapeutic in the sample from the host.

[0011] In an exemplary embodiment, the receptor is an antibody. In an exemplary embodiment, the receptor further comprises a non-isotopic signal-generating moiety. In another exemplary embodiment, the PI is a member selected from tipranavir, darunavir and tenofovir. In yet another exemplary embodiment, the NRTI is lamivudine. In yet another exemplary embodiment, the EI is maraviroc. In still another exemplary embodiment, the


method is a homogeneous immunoassay. In some exemplary embodiments, the detecting further comprises mixing the solution containing the receptor-anti-HIV therapeutic complex with a hapten-reactive partner conjugate comprising the met-sensitive moiety and a non-isotopic signal generating moiety; measuring the amount of the receptor bound to the hapten-reactive partner conjugate by monitoring a signal generated by the non-isotopic signal generating moiety; and correlating the signal with the presence or the concentration of the anti-HIV therapeutic in the sample. In other exemplary embodiments, the non-isotopic signal generating moiety is a member selected from an enzyme, a fluorogenic compound, a chemiluminescent compound, and combinations thereof. In another exemplary embodiment, the enzyme is glucose-6-phosphate dehydrogenase. In another exemplary embodiment, the met-sensitive moiety is a member selected from:




(H3),




(H4),




(H5),




(H6),




(H7),




(H8);




(K1),




(K2),




(K3);




(K4);



(N1);



(N2); and



(N3).

- 5 [0012] In a second aspect, the present invention provides a compound having the structure: $I-(X)_k-(C=O)_m-(Y)_n-(L)_p-Q$. In this structure, I is a met-sensitive moiety of an anti-HIV therapeutic, wherein the anti-HIV therapeutic is a member selected from PI, NRTI and EI. X is a member selected from O, NH, S, and CH_2 . Y is a member selected from O, NH, CH_2 , OH, and CH_2-S . The symbols k, m, n, and p represent integers independently selected from 0
- 10 and 1. L is a linker consisting of from 1 to 40 carbon atoms arranged in a straight chain or a branched chain, saturated or unsaturated, optionally comprising carbonyl or carboxy moieties and containing up to two ring structures and 0-20 heteroatoms, with the provision that not more than two heteroatoms may be linked in sequence. Q, along with the atoms to which it is attached, forms a reactive functional moiety selected from the group consisting of amines,
- 15 acids, esters, halogens, isocyanates, isothiocyanates, thiols, imidoesters, anhydrides, maleimides, thiolactones, diazonium groups and aldehydes. In another exemplary embodiment, the PI is a member selected from tipranavir, darunavir and tenofovir. In another exemplary embodiment, the NRTI is lamuvidine. In another exemplary embodiment, the EI

is maraviroc. In yet another exemplary embodiment, I is a member selected from (H3), (H4), (H5), (H6), (H7), (H8), (K1), (K2), (K3), (K4), (N1), (N2) and (N3). In still another exemplary embodiment, the symbol k represents 1, X is O, the symbol m represents 0, the symbol n represents 0, the symbol p represents 0, Q is succinimide, and I is a member selected from (H3), (H4), (H5), (H6), (H7), (H8), (K1), (K2), (K3), (K4), (N1), (N2) and (N3). In still another exemplary embodiment, the symbol k represents 1, X is O, the symbol m represents 0, the symbol n represents 0, the symbol p represents 0, Q is α haloacetyl, and I is a member selected from (H3), (H4), (H5), (H6), (H7), (H8), (K1), (K2), (K3), (K4), (N1), (N2) and (N3). In an exemplary embodiment, the invention provides a receptor that specifically binds to the compound having the structure: $I-(X)_k-(C=O)_m-(Y)_n-(L)_p-Q$. In an exemplary embodiment, the receptor is an antibody.

[0013] In a third aspect, the invention provides a compound having the structure: $[I-(X)_k-(C=O)_m-(Y)_n-(L)_p-Z]_r-P$. In this structure, I, X, Y, L, k, m, n, and p are as described above. Z, along with the atoms to which it is attached, forms a moiety selected from the group consisting of -CONH-, -NHCO-, -NHCONH-, -NHCSNH-, -OCONH-, -NHOCO-, -S-, -NH(C=NH)-, -N=N-, and -NH-, -CH₂CO-, and maleimides. P is a member selected from an immunogenic carrier, a non-isotopic signal generating moiety, solid support, a polypeptide, polysaccharide, a synthetic polymer, and combinations thereof. The symbol r represents a number from 1 to the number of hapten binding sites in P. In an exemplary embodiment, PI is a member selected from from tipranavir, darunavir and tenofovir. In another exemplary embodiment, NRTI is lamuvidine. In yet another exemplary embodiment, the EI is maraviroc. In yet another exemplary embodiment, I is a member selected from (H3), (H4), (H5), (H6), (H7), (H8), (K1), (K2), (K3), (K4), (N1), (N2) and (N3). In an exemplary embodiment, the invention provides an receptor that specifically binds to the compound having the structure: $[I-(X)_k-(C=O)_m-(Y)_n-(L)_p-Z]_r-P$.

[0014] In a fourth aspect, the invention provides an antigen for generating a receptor specific for a met-sensitive moiety of an anti-HIV therapeutic. In an exemplary embodiment, the receptor is an antibody. In another exemplary embodiment, the receptor specifically binds to a hapten comprising a met-sensitive moiety. In another exemplary embodiment, the receptor is selected from a Fab, Fab', F(ab')₂, Fv fragment, and a single-chain antibody. In another exemplary embodiment, the receptor is specific for a met-sensitive moiety of tipranavir and has 10% or less cross-reactivity with amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, darunavir and tenofovir. In another exemplary

embodiment, the receptor is specific for a met-sensitive moiety of darunavir and has 10% or less cross-reactivity with amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir and tenofovir. In another exemplary embodiment, the receptor is specific for a met-sensitive moiety of tenofovir and has 10% or less cross-reactivity with
5 amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, darunavir and tipranavir. In another exemplary embodiment, the receptor is specific for a met-sensitive moiety of a member selected from tipranavir, darunavir and tenofovir and has 10% or less cross-reactivity with NRTIs and EIs. In another exemplary embodiment, the receptor is specific for a met-sensitive moiety of lamuvidine and has 10% or less cross-reactivity with
10 other NRTIs, as well as PIs and EIs. In another exemplary embodiment, the receptor is specific for a met-sensitive moiety of maraviroc and has 10% or less cross-reactivity with other EIs, as well as PIs and NRTIs. In another exemplary embodiment, the receptors have 5% or less cross-reactivity with the anti-HIV therapeutics that it was not specifically raised against. In another exemplary embodiment, the receptors have 3% or less cross-reactivity
15 with the anti-HIV therapeutics that it was not specifically raised against. In another exemplary embodiment, the receptors have 1% or less cross-reactivity with the anti-HIV therapeutics that it was not specifically raised against. In another exemplary embodiment, I is a member selected from (H3), (H4), (H5), (H6), (H7), (H8), (K1), (K2), (K3), (K4), (N1), (N2) and (N3), and the receptor is a monoclonal antibody. In another exemplary
20 embodiment, the invention is a receptor that substantially competes with the binding of the monoclonal antibody that specifically binds a met-sensitive moiety of the invention. This met-sensitive moiety which the receptor specifically binds can be part of a hapten or a hapten-reactive-partner conjugate. In another exemplary embodiment, the invention is a receptor that substantially competes with the binding of the monoclonal antibody that
25 specifically binds a met-sensitive moiety of the invention. In some embodiments, the met-sensitive moiety is a member selected from (H3), (H4), (H5), (H6), (H7), (H8), (K1), (K2), (K3), (K4), (N1), (N2) and (N3). In another exemplary embodiment, the invention is a receptor that substantially competes with the binding of the monoclonal antibody that
30 specifically binds a met-sensitive moiety of the invention. In some embodiments, the receptor further comprises an antigen-binding domain.


[0015] In a fifth aspect, the invention provides a method of generating antibodies, comprising administering a compound to a mammal, the compound having the structure: $[I-(X)_k-(C=O)_m-(Y)_n-(L)_p-Z]_r-P$. In this structure, I, X, Y, L, Z, P, k, m, n, p, and r are as described above. In an exemplary embodiment, PI is a member selected from amprenavir, tipranavir, darunavir and tenofovir. In another exemplary embodiment, NRTI is lamuvidine. In yet another exemplary embodiment, the EI is maraviroc. In yet another exemplary embodiment, I is a member selected from (H3), (H4), (H5), (H6), (H7), (H8), (K1), (K2), (K3), (K4), (N1), (N2) and (N3).

[0016] In a sixth aspect, the invention provides a kit for determining, in a sample from a host, the presence or the concentration of an anti-HIV therapeutic which inhibits HIV propagation. The anti-HIV therapeutic is a member selected from a HIV protease inhibitor (PI) and a nucleoside HIV reverse transcriptase inhibitor (NRTI) and the anti-HIV therapeutic comprises a met-sensitive moiety that is transformed by the host to yield an inactivated metabolic product. The kit comprises: (a) a receptor specific for the met-sensitive moiety where the receptor does not bind to the inactivated metabolic product, thus yielding a receptor-anti-HIV therapeutic complex; (b) a calibration standard; and (c) instructions on the use of the kit. In an exemplary embodiment, the kit further comprises (d) a hapten-reactive partner conjugate comprising the met-sensitive moiety and a non-isotopic signal generating moiety. In another exemplary embodiment, the non-isotopic signal generating moiety is a member selected from an enzyme, a fluorogenic compound, a chemiluminescent compound, and combinations thereof. In an exemplary embodiment, PI is a member selected from tipranavir, darunavir and tenofovir. In another exemplary embodiment, NRTI is lamuvirdine. In yet another exemplary embodiment, the EI is maraviroc. In yet another exemplary embodiment, I is a member selected from (H3), (H4), (H5), (H6), (H7), (H8), (K1), (K2), (K3), (K4), (N1), (N2) and (N3). In other exemplary embodiments, the calibration standard comprises a matrix which is a member selected from human serum and buffered synthetic matrix.


[0017] The present invention also enables the determination of the presence or the concentration of PIs or NRTIs or EIs, both active and inactive, in an sample through a "PI Derivative" or a "NRTI Derivative" or an "EI Derivative" assay. Thus, in a seventh aspect, the invention provides a method for determining, in a sample from a host, the presence or the concentration of a PI Derivative or a NRTI Derivative or a EI Derivative which inhibits HIV

propagation. The method of this seventh aspect comprises combining, in a solution, the sample with a receptor specific for a PI Derivative or a NRTI Derivative or a EI Derivative, thereby generating a receptor-PI complex or a receptor-NRTI complex or a receptor-EI complex. Finally, the method comprises detecting the complex.


- 5 **[0018]** In an exemplary embodiment, the receptor is an antibody. In an exemplary embodiment, the receptor further comprises a non-isotopic signal-generating moiety. In an exemplary embodiment, PI is a member selected from tipranavir, darunavir and tenofovir. In another exemplary embodiment, NRTI is lamuvidine. In yet another exemplary embodiment, the EI is maraviroc. In still another exemplary embodiment, the method is a homogeneous
- 10 immunoassay. In some exemplary embodiments, the detecting further comprises mixing the solution containing the receptor-PI complex or receptor-NRTI complex or receptor-EI complex with a hapten-reactive partner conjugate comprising the met-sensitive moiety and a non-isotopic signal generating moiety; measuring the amount of the receptor bound to the hapten-reactive partner conjugate by monitoring a signal generated by the non-isotopic signal
- 15 generating moiety; and correlating the signal with the presence or the concentration of the receptor-PI complex or receptor-NRTI complex or receptor-EI complex in the sample. In other exemplary embodiments, the non-isotopic signal generating moiety is a member selected from an enzyme, a fluorogenic compound, a chemiluminescent compound, and combinations thereof. In another exemplary embodiment, the enzyme is glucose-6-phosphate
- 20 dehydrogenase. In another exemplary embodiment, the PI Derivative or NRTI Derivative or EI Derivative is a member selected from **(H9)**, **(H10)**, **(H11)**, **(H12)**, **(K5)**, **(K6)**, **(L1)**, **(M1)** and **(M2)**.




(H9);




(H10);




(H11);




(H12),




(K5),




(K6),



(L1),



(M1), and



(M2).

5

[0019] In an eighth aspect, the present invention provides a compound having the structure: $I-(X)_k-(C=O)_m-(Y)_n-(L)_p-Q$. In this structure, I is a PI Derivative or a NRTI Derivative or an EI Derivative. X is a member selected from O, NH, S, and CH_2 . Y is a member selected

from O, NH, CH₂, OH, and CH₂-S. The symbols k, m, n, and p represent integers independently selected from 0 and 1. L is a linker consisting of from 1 to 40 carbon atoms arranged in a straight chain or a branched chain, saturated or unsaturated, optionally comprising carbonyl or carboxy moieties and containing up to two ring structures and 0-20 heteroatoms, with the provision that not more than two heteroatoms may be linked in sequence. Q, along with the atoms to which it is attached, forms a reactive functional moiety selected from the group consisting of amines, acids, esters, halogens, isocyanates, isothiocyanates, thiols, imidoesters, anhydrides, maleimides, thiolactones, diazonium groups and aldehydes. In an exemplary embodiment, PI is a member selected from tipranavir, darunavir and tenofovir. In another exemplary embodiment, NRTI is lamuvidine. In yet another exemplary embodiment, the EI is maraviroc. In yet another exemplary embodiment, I is a member selected from (H9), (H10), (H11), (H12), (K5), (K6), (L1), (M1) and (M2). In still another exemplary embodiment, the symbol k represents 1, X is O, the symbol m represents 0, the symbol n represents 0, the symbol p represents 0, Q is succinimide, and I is a member selected from (H9), (H10), (H11), (H12), (K5), (K6), (L1), (M1) and (M2). In still another exemplary embodiment, the symbol k represents 1, X is O, the symbol m represents 0, the symbol n represents 0, the symbol p represents 0, Q is α haloacetyl, and I is selected from (H9), (H10), (H11), (H12), (K5), (K6), (L1), (M1) and (M2). In an exemplary embodiment, the invention provides a receptor that specifically binds to the compound having the structure: **I-(X)_k-(C=O)_m-(Y)_n-(L)_p-Q**. In an exemplary embodiment, the receptor is an antibody.

[0020] In a ninth aspect, the invention provides a compound having the structure: **[I-(X)_k-(C=O)_m-(Y)_n-(L)_p-Z]_r-P**. In this structure, I can be a PI Derivative of a PI, or a NRTI Derivative of a NRTI, or an EI Derivative of an EI. X, Y, L, k, m, n, and p are as described above. Z, along with the atoms to which it is attached, forms a moiety selected from the group consisting of -CONH-, -NHCO-, -NHCONH-, -NHCSNH-, -OCONH-, -NHOCO-, -S-, -NH(C=NH)-, -N=N-, and -NH-, -CH₂CO-, and maleimides. P is a member selected from an immunogenic carrier, a non-isotopic signal generating moiety, solid support, a polypeptide, polysaccharide, a synthetic polymer, and combinations thereof. The symbol r represents a number from 1 to the number of hapten binding sites in P. In an exemplary embodiment, PI is a member selected from tipranavir, darunavir and tenofovir. In another exemplary embodiment, NRTI is lamuvidine. In yet another exemplary embodiment, the EI is maraviroc. In yet another exemplary embodiment, I is a member selected from selected from

(H9), (H10), (H11), (H12), (K5), (K6), (L1), (M1) and (M2). In an exemplary embodiment, the invention provides a receptor that specifically binds to the compound having the structure: $[I-(X)_k-(C=O)_m-(Y)_n-(L)_p-Z]_r-P$.

[0021] In a tenth aspect, the invention provides an antigen for generating a receptor specific for a PI Derivative of a PI or a NRTI Derivative of a NRTI or an EI Derivative of an EI. In an exemplary embodiment, the receptor is an antibody. In another exemplary embodiment, the receptor specifically binds to a hapten comprising a NRTI Derivative. In another exemplary embodiment, the receptor is selected from a Fab, Fab', F(ab')₂, Fv fragment, and a single-chain antibody. In another exemplary embodiment, the receptor is specific for a PI Derivative of tipranavir and has 10% or less cross-reactivity with amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, darunavir and tenofovir. In another exemplary embodiment, the receptor is specific for a PI Derivative of darunavir and has 10% or less cross-reactivity with amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir and tenofovir. In another exemplary embodiment, the receptor is specific for a PI Derivative of tenofovir and has 10% or less cross-reactivity with amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, darunavir and tipranavir. In another exemplary embodiment, the receptor is specific for a PI Derivative of a member selected from tipranavir, darunavir and tenofovir and has 10% or less cross-reactivity with NRTIs and EIs. In another exemplary embodiment, the receptor is specific for a NRTI Derivative of lamuvidine and has 10% or less cross-reactivity with other NRTIs, as well as PIs and EIs. In another exemplary embodiment, the receptor is specific for a EI Derivative of maraviroc and has 10% or less cross-reactivity with other EIs, as well as PIs and NRTIs. In another exemplary embodiment, the receptors have 5% or less cross-reactivity with the anti-HIV therapeutics that it was not specifically raised against. In another exemplary embodiment, the receptors have 3% or less cross-reactivity with the anti-HIV therapeutics that it was not specifically raised against. In another exemplary embodiment, the receptors have 1% or less cross-reactivity with the anti-HIV therapeutics that it was not specifically raised against. In another exemplary embodiment, I is a member selected from (H9), (H10), (H11), (H12), (K5), (K6), (L1), (M1) and (M2), and the receptor is a monoclonal antibody. In another exemplary embodiment, the invention is a receptor that substantially competes with the binding of the monoclonal antibody that specifically binds a PI Derivative or a NRTI Derivative or an EI Derivative of the invention. This PI Derivative or NRTI Derivative or EI Derivative which the receptor specifically binds can be part of a hapten or a hapten-reactive-

partner conjugate. In another exemplary embodiment, the invention is a receptor that substantially competes with the binding of the monoclonal antibody that specifically binds a PI Derivative or a NRTI Derivative or an EI Derivative of the invention. In some embodiments, the PI Derivative or NRTI Derivative or EI Derivative is a member selected from (H9), (H10), (H11), (H12), (K5), (K6), (L1), (M1) and (M2). In another exemplary embodiment, the invention is a receptor that substantially competes with the binding of the monoclonal antibody that specifically binds a PI Derivative or a NRTI Derivative or an EI Derivative of the invention. In another exemplary embodiment, the invention is a receptor that substantially competes with the binding of the receptor that specifically binds a PI Derivative or a NRTI Derivative or an EI Derivative of the invention. In some embodiments, the receptor further comprises an antigen-binding domain.

[0022] In an eleventh aspect, the invention provides a method of generating antibodies, comprising administering a compound to a mammal, the compound having the structure: $[I-(X)_k-(C=O)_m-(Y)_n-(L)_p-Z]_r-P$. In this structure, I can be a PI Derivative of a PI or a NRTI Derivative of a NRTI or an EI Derivative of an EI. X, Y, L, Z, P, k, m, n, p, and r are as described above. In an exemplary embodiment, PI is a member selected from tipranavir, darunavir and tenofovir. In another exemplary embodiment, NRTI is lamuvidine. In yet another exemplary embodiment, the EI is maraviroc. In yet another exemplary embodiment, I is a member selected from (H9), (H10), (H11), (H12), (K5), (K6), (L1), (M1) and (M2).

[0023] In a twelfth aspect, the invention provides a kit for determining, in a sample from a host, the presence or the concentration of a PI or a NRTI or an EI which inhibits HIV propagation. The kit comprises: (a) a receptor specific for the PI Derivative or the NRTI Derivative or the EI Derivative. The kit can optionally comprise (b) a calibration standard; and (c) instructions on the use of the kit. In an exemplary embodiment, the kit optionally further comprises (d) a hapten-reactive partner conjugate comprising PI Derivative or the NRTI Derivative or the EI Derivative and a non-isotopic signal generating moiety. In another exemplary embodiment, the non-isotopic signal generating moiety is a member selected from an enzyme, a fluorogenic compound, a chemiluminescent compound, and combinations thereof. In an exemplary embodiment, PI is a member selected from tipranavir, darunavir and tenofovir. In another exemplary embodiment, NRTI is lamuvidine. In yet another exemplary embodiment, the EI is maraviroc. In yet another exemplary embodiment, I is a member selected from (H9), (H10), (H11), (H12), (K5), (K6), (L1), (M1) and (M2).

In other exemplary embodiments, the calibration standard comprises a matrix which is a member selected from human serum and buffered synthetic matrix.

BRIEF DESCRIPTION OF THE DRAWINGS

[0024] FIG. 1 is a calibration curve, alternatively known as a dose-response curve, for the anti-HIV therapeutic tipranavir. This graph is a representation of the change in optical density as a function of the concentration of tipranavir.

DETAILED DESCRIPTION OF THE INVENTION

I. Introduction

[0025] The compounds, methods, and kits of the invention provide several new approaches to anti-HIV therapeutic drug monitoring. In a first new approach, the presence or the concentration of a PI or NRTI or EI in a sample can be ascertained through a non-isotopic immunoassay. This is accomplished through the attachment of a reactive functional group to a PI or NRTI or EI, thus forming a "PI Derivative" or a "NRTI Derivative" or an "EI Derivative". This PI Derivative or NRTI Derivative or EI Derivative can be utilized in TDM assays as is, or as further coupled to a reactive partner, in order to measure the amount of PI or NRTI or EI, both active and inactive, in the sample.

[0026] The invention comprises compounds, methods, and kits which utilize PI Derivatives or NRTI Derivatives or EI Derivatives. On one level, the invention comprises a hapten, which contains the PI Derivative or NRTI Derivative or EI Derivative. The hapten can optionally further comprise a reactive functional group, linker, or a reactive functional group attached through a linker. The hapten can also optionally be attached to a reactive partner, such as a solid support, non-isotopic signal generating moiety, an immunogenic carrier, *e.g.*, a carrier protein or enzyme, or combinations thereof. The hapten can be optionally linked to a reactive partner which comprises a signal-generating moiety in order to create an enzyme conjugate. Conjugation of the hapten with an immunogenic carrier can form a PI Derivative Antigen or a NRTI Derivative Antigen or an EI Derivative Antigen, alternatively known as an immunogen. These immunogens can be used to raise antibodies against PIs or NRTIs or EIs, respectively. The antibodies produced, or receptors based on these antibodies, can be incorporated into immunoassays, which determine the amount of the PI or NRTI or EI in a subject. The materials described above can be incorporated into methods of determining the presence or the concentration of PI or NRTI or EI in a sample, as well as methods of raising

antibodies to these materials. Finally the materials described above can be incorporated into kits which can help assay anti-HIV therapeutic drug levels in patients.

[0027] In a second new approach, for the first time, differentiation is made between active and inactive forms of an anti-HIV therapeutic in a patient. Quantifying the active, or metabolically sensitive ("met-sensitive"), forms of PIs and NRTIs and EIs provides several benefits to the individual and the community. First, monitoring of the active drug presence in a patient allows for the tailoring of a regimen that fits the patient's particular pharmacologic profile. This allows for more efficient dosing, better treatment, and the prolonged life of the subject. Second, more effective dosing leads to greater suppression of the virus, which in turn reduces the introduction of new HIV mutations in the community. This combination of more effective dosing and reduction in HIV mutations makes this invention a significant contribution to the art.

[0028] The invention comprises compounds, methods, and kits which utilize met-sensitive moieties of anti-HIV therapeutics. On one level, the invention comprises a hapten, which can contain the met-sensitive moiety. The hapten can optionally further comprise a reactive functional group, linker, or a reactive functional group attached through a linker. The hapten can also optionally be attached to a reactive partner, such as a solid support, non-isotopic signal generating moiety, an immunogenic carrier, *e.g.*, a carrier protein or enzyme, or combinations thereof. The hapten can be optionally linked to a reactive partner which comprises a non-isotopic signal-generating moiety in order to create an enzyme conjugate. Conjugation of the hapten with an immunogenic carrier can form a met-sensitive antigen, alternatively known as an immunogen. These immunogens can be used to raise antibodies against the met-sensitive moieties of anti-HIV therapeutics. The antibodies produced can be incorporated into immunoassays, which determine the amount of the active anti-HIV therapeutic in a subject. The materials described above can be incorporated into methods of determining the concentration of anti-HIV therapeutics in a sample, as well as methods of raising antibodies to these materials. Finally the materials described above can be incorporated into kits which can help assay anti-HIV therapeutic drug levels in patients.

II. Definitions

[0029] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this

invention is related. The following terms are defined for purposes of the invention as described herein.

[0030] The symbol , whether utilized as a bond or displayed perpendicular to a bond indicates the point at which the displayed moiety is attached to the remainder of the molecule, solid support, etc.

[0031] Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.

[0032] Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are encompassed within the scope of the present invention.

[0033] The compounds of the invention may be prepared as a single isomer (*e.g.*, enantiomer, *cis-trans*, positional, diastereomer) or as a mixture of isomers. In a preferred embodiment, the compounds are prepared as substantially a single isomer. Methods of preparing substantially isomerically pure compounds are known in the art. For example, enantiomerically enriched mixtures and pure enantiomeric compounds can be prepared by using synthetic intermediates that are enantiomerically pure in combination with reactions that either leave the stereochemistry at a chiral center unchanged or result in its complete inversion. Alternatively, the final product or intermediates along the synthetic route can be resolved into a single stereoisomer. Techniques for inverting or leaving unchanged a particular stereocenter, and those for resolving mixtures of stereoisomers are well known in the art and it is well within the ability of one of skill in the art to choose and appropriate method for a particular situation. *See, generally, Furniss et al. (eds.), Vogel's Encyclopedia of Practical Organic Chemistry*, 5th ed., Longman Scientific and Technical Ltd., Essex, 1991, pp. 809-816; and Heller, *Acc. Chem. Res.* **23**: 128 (1990).

[0034] The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as, for example, tritium (^3H), iodine-125 (^{125}I) or carbon-14 (^{14}C). All isotopic variations of the compounds of the

present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.

[0035] Where substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents, which would result from writing the structure from right to left, *e.g.*, -CH₂O- is intended to also recite -OCH₂-.

[0036] The term “acyl” or “alkanoyl” by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and an acyl radical on at least one terminus of the alkane radical. The “acyl radical” is the group derived from a carboxylic acid by removing the -OH moiety therefrom.

[0037] The term “alkyl,” by itself or as part of another substituent means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include divalent (“alkylene”) and multivalent radicals, having the number of carbon atoms designated (*i.e.* C₁-C₁₀ means one to ten carbons). Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butylnyl, and the higher homologs and isomers. The term “alkyl,” unless otherwise noted, is also meant to include those derivatives of alkyl defined in more detail below, such as “heteroalkyl.” Alkyl groups that are limited to hydrocarbon groups are termed “homoalkyl”.

[0038] Exemplary alkyl groups of use in the present invention contain between about one and about twenty five carbon atoms (*e.g.* methyl, ethyl and the like). Straight, branched or cyclic hydrocarbon chains having eight or fewer carbon atoms will also be referred to herein as “lower alkyl”. In addition, the term “alkyl” as used herein further includes one or more substitutions at one or more carbon atoms of the hydrocarbon chain fragment.

[0039] The terms “alkoxy,” “alkylamino” and “alkylthio” (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.

[0040] The term “heteroalkyl,” by itself or in combination with another term, means, unless otherwise stated, a straight or branched chain, or cyclic carbon-containing radical, or combinations thereof, consisting of the stated number of carbon atoms and at least one heteroatom which is a member selected from the group consisting of O, N, Si, P and S, and wherein the nitrogen, phosphorous and sulfur atoms are optionally oxidized, and the nitrogen heteroatom is optionally be quaternized. The heteroatom(s) O, N, P, S and Si may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Examples include, but are not limited to, -CH₂-CH₂-O-CH₃, -CH₂-CH₂-NH-CH₃, -CH₂-CH₂-N(CH₃)-CH₃, -CH₂-S-CH₂-CH₃, -CH₂-CH₂-S(O)-CH₃, -CH₂-CH₂-S(O)₂-CH₃, -CH=CH-O-CH₃, -Si(CH₃)₃, -CH₂-CH=N-OCH₃, and -CH=CH-N(CH₃)-CH₃. Up to two heteroatoms may be consecutive, such as, for example, -CH₂-NH-OCH₃ and -CH₂-O-Si(CH₃)₃. Similarly, the term “heteroalkylene” by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH₂-CH₂-S-CH₂-CH₂- and -CH₂-S-CH₂-CH₂-NH-CH₂-. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (*e.g.*, alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula -C(O)₂R'- represents both -C(O)₂R'- and -R'C(O)₂-.

[0041] The terms “cycloalkyl” and “heterocycloalkyl”, by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl”, respectively. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.

[0042] The term “aryl” means, unless otherwise stated, a polyunsaturated, aromatic moiety that can be a single ring or multiple rings (preferably from 1 to 3 rings), which are fused together or linked covalently. The term “heteroaryl” refers to aryl groups (or rings) that contain from one to four heteroatoms which are members selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalyl, 5-quinoxalyl, 3-quinolyl, tetrazolyl, benzo[b]furanyl, benzo[b]thienyl, 2,3-dihydrobenzo[1,4]dioxin-6-yl, benzo[1,3]dioxol-5-yl and 6-quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.

[0043] For brevity, the term “aryl” when used in combination with other terms (*e.g.*, aryloxy, arylthioxy, arylalkyl) includes both aryl and heteroaryl rings as defined above. Thus, the term “arylalkyl” is meant to include those radicals in which an aryl group is attached to an alkyl group (*e.g.*, benzyl, phenethyl, pyridylmethyl and the like) including those alkyl groups in which a carbon atom (*e.g.*, a methylene group) has been replaced by, for example, an oxygen atom (*e.g.*, phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naphthyloxy)propyl, and the like).

[0044] Each of the above terms (*e.g.*, “alkyl,” “heteroalkyl,” “aryl” and “heteroaryl”) includes both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.

[0045] Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) are generically referred to as “alkyl group substituents,” and they can be one or more of a variety of groups selected from, but not limited to: -OR', =O, =NR', =N-OR', -NR'R'', -SR', -halogen, -SiR'R''R''', -OC(O)R', -C(O)R', -CO₂R', -CONR'R'', -OC(O)NR'R'', -NR'C(O)R', -NR'-C(O)NR''R''',

-NR'C(O)₂R', -NR-C(NR'R''R''')=NR''', -NR-C(NR'R'')=NR'', -S(O)R', -S(O)₂R', -S(O)₂NR'R'', -NRSO₂R', -CN and -NO₂ in a number ranging from zero to (2m'+1), where m' is the total number of carbon atoms in such radical. R', R'', R''' and R'''' each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, *e.g.*, aryl substituted with 1-3 halogens, substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups. When a compound of the invention includes more than one R group, for example, each of the R groups is independently selected as are each R', R'', R''' and R'''' groups when more than one of these groups is present. When R' and R'' are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, -NR'R'' is meant to include, but not be limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term "alkyl" is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (*e.g.*, -CF₃ and -CH₂CF₃) and acyl (*e.g.*, -C(O)CH₃, -C(O)CF₃, -C(O)CH₂OCH₃, and the like).

[0046] Similar to the substituents described for the alkyl radical, substituents for the aryl and heteroaryl groups are generically referred to as "aryl group substituents." The substituents are selected from, for example: halogen, -OR', =O, =NR', =N-OR', -NR'R'', -SR', -halogen, -SiR'R''R''', -OC(O)R', -C(O)R', -CO₂R', -CONR'R'', -OC(O)NR'R'', -NR'C(O)R', -NR'-C(O)NR''R''', -NR'C(O)₂R', -NR-C(NR'R''R''')=NR''', -NR-C(NR'R'')=NR'', -S(O)R', -S(O)₂R', -S(O)₂NR'R'', -NRSO₂R', -CN and -NO₂, -R', -N₃, -CH(Ph)₂, fluoro(C₁-C₄)alkoxy, and fluoro(C₁-C₄)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R', R'', R''' and R'''' are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. When a compound of the invention includes more than one R group, for example, each of the R groups is independently selected as are each R', R'', R''' and R'''' groups when more than one of these groups is present. In the schemes that follow, the symbol X represents "R" as described above.

[0047] Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -T-C(O)-(CRR')_q-U-, wherein T and U are independently -NR-, -O-, -CRR'- or a single bond, and q is an integer of from 0 to 3. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH₂)_r-B-, wherein A and B are

independently $-\text{CRR}'-$, $-\text{O}-$, $-\text{NR}-$, $-\text{S}-$, $-\text{S}(\text{O})-$, $-\text{S}(\text{O})_2-$, $-\text{S}(\text{O})_2\text{NR}'-$ or a single bond, and r is an integer of from 1 to 4. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula

5 $-(\text{CRR}')_s-\text{X}-(\text{CR}''\text{R}''')_d-$, where s and d are independently integers of from 0 to 3, and X is $-\text{O}-$, $-\text{NR}'-$, $-\text{S}-$, $-\text{S}(\text{O})-$, $-\text{S}(\text{O})_2-$, or $-\text{S}(\text{O})_2\text{NR}'-$. The substituents R , R' , R'' and R''' are preferably independently selected from hydrogen or substituted or unsubstituted (C_1 - C_6)alkyl.

[0048] As used herein, the term "heteroatom" includes oxygen (O), nitrogen (N), sulfur (S), phosphorus (P) and silicon (Si).

10 [0049] The term "amino" or "amine group" refers to the group $-\text{NR}'\text{R}''$ (or $\text{N}^+\text{RR}'\text{R}''$) where R , R' and R'' are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aryl alkyl, substituted aryl alkyl, heteroaryl, and substituted heteroaryl. A substituted amine being an amine group wherein R' or R'' is other than hydrogen. In a primary amino group, both R' and R'' are hydrogen, whereas in a
15 secondary amino group, either, but not both, R' or R'' is hydrogen. In addition, the terms "amine" and "amino" can include protonated and quaternized versions of nitrogen, comprising the group $-\text{N}^+\text{RR}'\text{R}''$ and its biologically compatible anionic counterions.

[0050] The term "aqueous solution" as used herein refers to a solution that is predominantly water and retains the solution characteristics of water. Where the aqueous
20 solution contains solvents in addition to water, water is typically the predominant solvent.

[0051] "Antibody", as used herein, refers to a protein functionally defined as a binding protein and structurally defined as comprising an amino acid sequence that is recognized by one of skill as being derived from the framework region of an immunoglobulin encoding gene of an animal producing antibodies. It includes whole antibody, functional fragments,
25 modification or derivatives of the antibody. It can also be genetically manipulated product, or chimeric antibody.

[0052] "Antigen", as used herein, refers to a compound that is capable of stimulating an immune response.

[0053] "Antibody-anti-HIV therapeutic complex", as used herein, refers to the interaction
30 of an antibody with an anti-HIV therapeutic. In an exemplary embodiment, the interaction is selected from hydrogen bonding, van der Waals interactions, repulsive electronic

interactions, attractive electronic interactions, hydrophobic interactions, hydrophilic interactions and combinations thereof. In another exemplary embodiment, the interaction is covalent bonding or ionic bonding. Examples of antibody-anti-HIV therapeutic complexes include antigen-antibody, hapten-antibody, anti-HIV therapeutic fragment-antibody.

5 **[0054]** "Buffered synthetic matrix", as used herein, refers to an aqueous solution comprising non-human constituents. Buffered synthetic matrices may include surface active additives, organic solvents, defoamers, buffers, surfactants, and anti-microbial agents. Surface active additives are introduced to maintain hydrophobic or low-solubility compounds in solution, and stabilize matrix components. Examples include bulking agents such as
10 betalactoglobulin (BLG) or polyethyleneglycol (PEG); defoamers and surfactants such as Tween-20, Plurafac A38, Triton X-100, Pluronic 25R2, rabbit serum albumin (RSA), bovine serum albumin (BSA), and carbohydrates. Examples of organic solvents in buffered synthetic matrices include methanol and other alcohols. Various buffers may be used to maintain the pH of the synthetic matrix during storage. Illustrative buffers include HEPES,
15 borate, phosphate, carbonate, tris, barbital and the like. Anti-microbial agents also extend the storage life of the matrix. An example of an anti-microbial agent used in this invention includes 2-methyl-4-isothiazolin-3-one hydrochloride.

[0055] "Immunogenic carrier", as used herein, refers to any material which interacts with a hapten and stimulates an *in vitro* or *in vivo* immune response. Immunogenic carriers include
20 proteins, glycoproteins, complex polysaccharides and nucleic acids that are recognized as foreign and thereby elicit an immunologic response from the host. Examples of carrier substances include keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA).

[0056] "Calibration standard", as used herein, refers to an aqueous medium containing the anti-HIV therapeutic at a predetermined concentration. In an exemplary embodiment, a
25 series of these calibration standards are available at a series of predetermined concentrations. In another exemplary embodiment, the calibration standard is stable at ambient temperature. In yet another exemplary embodiment, the calibration standards are in a synthetic matrix. In yet another exemplary embodiment, the calibration standards are in a non-synthetic matrix such as human serum.

30 **[0057]** "Concentration of an anti-HIV therapeutic", as used herein, refers to the amount of anti-HIV therapeutic present in a sample. In an exemplary embodiment, the sample is synthetically produced, or taken from a mammal. The sample can be prepared in any

convenient medium which does not interfere with the assay. In some exemplary embodiments, the sample is urine, blood, serum, breast milk, plasma, or saliva.

[0058] "Conjugate", as used herein, refers to a molecule comprised of two or more moieties bound together, optionally through a linking group, to form a single structure. The binding can be made either by a direct connection (e.g. a chemical bond) between the subunits or by use of a linking group. Examples and methods of forming conjugates are further described in Hermanson, G. T., "Bioconjugate Techniques", Academic Press: New York, 1996; and "Chemistry of Protein Conjugation and Cross-linking" by S. S. Wong, CRC Press, 1993, herein incorporated by reference.

[0059] "HIV protease inhibitor (PI)", as used herein, refers to therapeutics that combats viral replication of HIV by blocking HIV's protease protein. This protein or enzyme is utilized by the virus to break up large viral proteins into smaller particles from which new HIV particles can be formed. PIs ensure that these new particles are immature and incapable of infecting new cells, thus inhibiting the HIV replication process.

[0060] "Homogeneous immunoassay", as used herein, refers to an assay method where the complex is typically not separated from unreacted reaction components, but instead the presence of the complex is detected by a property which at least one of the reactants acquires or loses as a result of being incorporated into the complex. Homogeneous assays known in the art include systems involving fluorochrome and fluorochrome quenching pairs on different reagents (U.S. Pat. Nos. 3,996,345, 4,161,515, 4,256,834, and 4,264,968); enzyme and enzyme inhibitor pairs on different reagents (U.S. Pat. Nos. 4,208,479 and 4,233,401); chromophore and chromophore modifier pairs on different reagents (U.S. Pat. No. 4,208,479); and latex agglutination assays (U.S. Pat. Nos. 3,088,875, 3,551,555, 4,205,954, and 4,351,824).

[0061] "Human serum", as used herein, refers to the aqueous portion of human blood remaining after the fibrin and suspended material (such as cells) have been removed.

[0062] "Inactivated metabolic product", as used herein, refers to the transformation of chemical compounds within a living system which reduces or eliminates its therapeutic efficacy.

[0063] "Inhibits HIV propagation", as used herein, refers to the viral load becoming significantly decreased or undetectable by the use of antiretroviral therapeutics, thus the risk

of ultimate therapeutic failure is minimized. The presence of HIV RNA in plasma reflects viral replication, which in the presence of inadequate medications can lead to the development of resistant viral strains. If the viral load is suppressed to undetectable levels, the development of resistance is minimized, prolonging the durability of the antiretroviral response.

[0064] "Met-sensitive moiety", as used herein, refers to a portion of an anti-HIV therapeutic to which an antibody binds. These met-sensitive portions are capable of binding specifically to corresponding antibodies, but do not themselves act as immunogens (or antigens) for preparation of the antibodies. Antibodies which recognize a met-sensitive portion can be prepared against compounds comprised of the defined portion linked to an immunogenic (or antigenic) carrier.

[0065] "Non-nucleoside HIV reverse transcriptase inhibitor (NNRTI)", as used herein, refers to chemical compounds that prevent HIV replication by inhibiting the reverse transcriptase enzyme. This enzyme creates a deoxyribonucleic acid, or DNA, copy of HIV's genome from its ribonucleic acid, or RNA, template. Disrupting this RNA to DNA transcription event prevents HIV replication by disrupting the insertion of HIV's genome into an infected cell's genome.

[0066] "NNRTI Derivative", as used herein, refers to chemical compounds which comprise an NNRTI molecule attached to one or more other moieties, such as linkers, reactive groups, etc. As a general rule, an NNRTI Derivative will not have a lower molecular weight than its respective NNRTI.

[0067] "Non-isotopic signal-generating moiety", as used herein, refers to chemical compounds which do not use radioactive nuclei for detection purposes. By way of example, a non-isotopic signal-generating moiety is an enzyme, fluorescent compound, or a luminescent compound.

[0068] "Transformed", as used herein, refers to the *in vivo* conversion of a chemical compound from an active form to an inactive form. In an exemplary embodiment, the chemical compound after transformation is less active or effective. In another exemplary embodiment, the molecular moiety that is transformed is metabolically sensitive.

[0069] The following abbreviations are used in the application: rt represents room temperature; ip represents interperitoneal; sc represents subcutaneous; FCA represents

Freund's Complete Adjuvant; IFA represents Freund's Incomplete Adjuvant; HBSS represents Hank's Buffered Saline Solution; DMEM represents Dulbecco's Modified Eagle's Media; and HAT media is Hypoxanthine Aminopterin, Thymidine media.

III. Haptens comprising Met-Sensitive Moieties, PI Derivatives or NRTI Derivatives or EI Derivatives

[0070] The essence of adaptive immunity is the ability of an organism to react to the presence of foreign substances and produce components (antibodies and cells) capable of specifically interacting with and protecting the host from their invasion. Not all foreign substances are capable of producing an immune response, however. Small molecules, although normally able to interact with the products of an immune response, often cannot cause a response on their own. These molecules are called haptens. Three examples of these haptens of use in this invention comprise met-sensitive moieties of PIs and NNRTIs and EIs, as well as PI Derivatives or NRTI Derivatives or EI Derivatives. These compounds are alternatively known as haptens, haptens comprising met-sensitive moieties, or haptens comprising PI Derivatives or NRTI Derivatives or EI Derivatives.

III. A. Hapten Examples

III. A. i) Haptens comprising PI Derivatives or Met-Sensitive Moieties of PI

[0071] PIs are an important new class of drugs which have made a significant impact on the health care of AIDS patients since the first PI, saquinavir, was introduced to the marketplace in 1995. PIs combat viral replication of HIV by blocking HIV protease. This protease breaks up large viral proteins into smaller particles from which new HIV particles can be formed. PIs ensure that these new particles are immature and incapable of infecting new cells, thus inhibiting the HIV replication process. There are currently eight FDA approved protease inhibitors: amprenavir (Agenerase), atazanavir (Reyataz), fosamprenavir (Lexiva), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), saquinavir (Fortovase), and tipranavir.

[0072] The cytochrome P450 (CYP) enzyme 3A4 is central to the metabolism of many drugs, including PIs (Flexner C. *et al. N Engl J Med* **338**:1281-1292 (1998)). The enzyme's activity serves to extensively metabolize and deactivate all currently known PIs, with the exception of nelfinavir, in hepatic microsomes as well as in the gastrointestinal tract. Therefore, it is important that antibodies used in an immunoassay be raised to that part of the molecule that undergoes metabolism in order to minimize cross-reactivity with deactivated metabolites. Consequently, the linkage both to the immunogenic carrier and the PI fragment

must be on the opposite end of the molecule which undergoes biotransformation. Antibody cross-reactivity can be further minimized by designing haptens with a minimum of those moieties possessed by both the parent PI and its biotransformed metabolite derivative.

[0073] Descriptions of the met-sensitive moieties of PI are discussed below.

5 *Tipranavir*

[0074] Tipranavir was shown to be metabolically stable. In preclinical pharmacokinetic studies and in *in vitro* rat, dog, and human primary hepatocyte incubations, tipranavir was stable (Koeplinger *et al.*, *Drug Metabolism and Disposition*, **27 (9)**: 986-991 (1999)). Plasma metabolic profiles of tipranavir in rats or dogs showed only the parent drug. *In vivo* studies
10 with tipranavir were consistent with the relative stability this compound exhibited *in vitro*.

Darunavir (TMC114)

[0075] Darunavir, also known as TMC114, is an inhibitor of the HIV-1 protease. It selectively inhibits the cleavage of HIV encoded Gag-Pol polyproteins in infected cells, thereby preventing the formation of mature virus particles. In vitro experiments with human
15 liver microsomes indicate that darunavir primarily undergoes oxidative metabolism. Darunavir is extensively metabolized by CYP enzymes, primarily by CYP3A. A mass balance study in healthy volunteers showed that after a single dose administration of 400 mg
14 ¹⁴C-darunavir, co-administered with 100 mg ritonavir, the majority of the radioactivity in the plasma was due to darunavir. At least 3 oxidative metabolites of darunavir have been
20 identified in humans; all showed activity that was at least 90% less than the activity of darunavir against wild-type HIV. (Tibotec, Inc. package insert).

Tenofovir

[0076] Tenofovir disoproxil fumarate (a prodrug of tenofovir) which is a fumaric acid salt of bis-isopropoxycarbonyloxymethyl ester derivative of tenofovir. In vivo tenofovir
25 disoproxil fumarate is converted to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate. Tenofovir exhibits activity against HIV-1 reverse transcriptase.

[0077] Tenofovir disoproxil fumarate requires initial diester hydrolysis for conversion to tenofovir and subsequent phosphorylations by cellular enzymes to form tenofovir
30 diphosphate. Tenofovir diphosphate inhibits the activity of HIV-1 reverse transcriptase by competing with the natural substrate deoxyadenosine 5'-triphosphate and, after incorporation

into DNA, by DNA chain termination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases α , β , and mitochondrial DNA polymerase γ .

[0078] In vitro studies indicate that neither tenofovir disoproxil nor tenofovir are substrates of CYP450 enzymes. Following IV administration of tenofovir, approximately 70–80% of the dose is recovered in the urine as unchanged tenofovir within 72 hours of dosing. Following a single dose, oral administration of Tenofovir disoproxil fumarate, the terminal elimination half-life of tenofovir is approximately 17 hours. After multiple oral doses of Tenofovir disoproxil fumarate 300 mg once daily (under fed conditions), $32 \pm 10\%$ of the administered dose is recovered in urine over 24 hours.

[0079] Tenofovir is eliminated by a combination of glomerular filtration and active tubular secretion. There may be competition for elimination with other compounds that are also renally eliminated.

III. A. ii) Haptens comprising NRTI Derivatives or Met-Sensitive Moieties of NRTI

Lamivudine

[0080] Lamivudine, also known as 3TC, the negative enantiomer of 2'-deoxy-3'-thiacytidine, is a dideoxynucleoside analogue used in combination with other agents in the treatment of human immunodeficiency virus type 1 (HIV-1) infection and as monotherapy in the treatment of hepatitis B virus (HBV) infection. Lamivudine undergoes anabolic phosphorylation by intracellular kinases to form lamivudine 5'-triphosphate, the active anabolite which prevents HIV-1 and HBV replication by competitively inhibiting viral reverse transcriptase and terminating proviral DNA chain extension. The drug is rapidly absorbed after oral administration, with maximum serum concentrations usually attained 0.5 to 1.5 hours after the dose. The absolute bioavailability is approximately 82 and 68% in adults and children, respectively. Lamivudine systemic exposure, as measured by the area under the serum drug concentration-time curve (AUC), is not altered when it is administered with food. Lamivudine is widely distributed into total body fluid, the mean apparent volume of distribution (Vd) being approximately 1.3 L/kg following intravenous administration. In pregnant women, lamivudine concentrations in maternal serum, amniotic fluid, umbilical cord and neonatal serum are comparable, indicating that the drug diffuses freely across the placenta. In postpartum women lamivudine is secreted into breast milk. The concentration of lamivudine in cerebrospinal fluid (CSF) is low to modest, being 4 to 8% of serum concentrations in adults and 9 to 17% of serum concentrations in children measured at 2 to 4

hours after the dose. In patients with normal renal function, about 5% of the parent compound is metabolized to the trans-sulphoxide metabolite, which is pharmacologically inactive. In patients with renal impairment, the amount of trans-sulphoxide metabolite recovered in the urine increases, presumably as a function of the decreased lamivudine elimination. As approximately 70% of an oral dose is eliminated renally as unchanged drug, the dose needs to be reduced in patients with renal insufficiency. Hepatic impairment does not affect the pharmacokinetics of lamivudine. Systemic clearance following single intravenous doses averages 20 to 25 L/h (approximately 0.3 L/h/kg). The dominant elimination half-life of lamivudine is approximately 5 to 7 hours, and the in vitro intracellular half-life of its active 5'-triphosphate anabolite is 10.5 to 15.5 hours and 17 to 19 hours in HIV-1 and HBV cell lines, respectively. Johnson, MA *et al.*, Clin. Pharmacokin. 1999 Jan;36(1):41-66.

III. A. iii) Haptens comprising EI Derivatives or Met-Sensitive Moieties of EI

Maraviroc

[0081] Maraviroc (UK-427,857) is a selective CCR5 antagonist with potent anti-human immunodeficiency virus type 1 (HIV-1) activity and favorable pharmacological properties that belongs to a new class of drugs called entry inhibitors. Maraviroc works through a different mechanism of action from currently marketed anti HIV drugs. Maraviroc belongs to category of compounds known as a chemokine receptor antagonist which blocks HIV infection of CD4 T-cells by blocking the CCR5 receptor. When the CCR5 receptor is unavailable, 'CCR5-tropic' HIV cannot engage with a CD4 T-cell to infect the cell.

[0082] Pharmacokinetic and metabolism studies have been performed in mouse, rat, dog, and human after single and multiple administration by oral and intravenous routes (Iker, K. *Drug Metab Dispos.* 2005 Apr;33(4):587-95) The compound has physicochemical properties that are borderline for good pharmacokinetics, being moderately lipophilic and basic, possessing a number of H-bonding functionalities, and with a molecular weight of 514. In animal species and humans, maraviroc undergoes some metabolism, with the parent compound being the major component present in the systemic circulation and excreta. Elimination of radioactive dose was primarily via the feces. In rat, the parent compound was secreted via bile and directly into the gastrointestinal tract. Metabolites were products of oxidative metabolism and showed a high degree of structural consistency across species.

III. B. Methods of Making the Haptens

[0083] In addition to the met-sensitive, PI Derivative or NRTI Derivative or EI Derivative moieties, the haptens of the invention can further comprise reactive functional groups, linkers, or both. Reactive functional groups and/or linkers can be used in order to create covalent linkages between the hapten and other compounds, such as reactive partners.

III. B. i) Reactive Functional Groups

[0084] Reactive functional groups can be represented by either Q, which represents a reactive functional group, or (-L-Q), which represents a reactive functional group Q that is attached to the met-sensitive moiety, PI Derivative or NRTI Derivative or EI Derivative, or the reactive partner by a covalent linkage L. In an exemplary embodiment, Q, along with the atoms to which it is attached, forms a reactive functional group which is a member selected from amines, carboxylic acids, esters, halogens, isocyanates, isothiocyanates, thiols, imidoesters, anhydrides, maleimides, thiolactones, diazonium groups, aldehydes, acrylamide, an acyl azide, an acyl nitrile, an alkyl halide, an aniline, an aryl halide, an azide, an aziridine, a boronate, a carboxylic acid, a diazoalkane, a haloacetamide, a halotriazine, a hydrazine, a hydrazide, an imido ester, a phosphoramidite, a reactive platinum complex, a sulfonyl halide, and a photoactivatable group. In another exemplary embodiment, the point of attachment of the reactive group to the met-sensitive moiety is designated by "~~~~".

III. B. ii) Linkers

[0085] In some embodiments, the reactive functional group further comprises a linker, L. The linker is used to covalently attach a reactive functional group to the met-sensitive moiety, PI Derivative or NRTI Derivative or EI Derivative of the invention. When present, the linker is a single covalent bond or a series of stable bonds. Thus, the reactive functional group may be directly attached (where the linker is a single bond) to the met-sensitive moiety, PI Derivative or NRTI Derivative or EI Derivative or attached through a series of stable bonds. When the linker is a series of stable covalent bonds the linker typically incorporates 1-20 nonhydrogen atoms selected from the group consisting of C, N, O, S, and P. In addition, the covalent linkage can incorporate a platinum atom, such as described in U.S. Patent No. 5,714,327. When the linker is not a single covalent bond, the linker may be any combination of stable chemical bonds, optionally including, single, double, triple or aromatic carbon-carbon bonds, as well as carbon-nitrogen bonds, nitrogen-nitrogen bonds, carbon-oxygen bonds, sulfur-sulfur bonds, carbon-sulfur bonds, phosphorus-oxygen bonds, phosphorus-nitrogen bonds, and nitrogen-platinum bonds. In an exemplary embodiment, the linker

incorporates less than 15 nonhydrogen atoms and are composed of a combination of ether, thioether, thiourea, amine, ester, carboxamide, sulfonamide, hydrazide bonds and aromatic or heteroaromatic bonds. Typically the linker is a single covalent bond or a combination of single carbon-carbon bonds and carboxamide, sulfonamide or thioether bonds. The following

5 moieties can be found in the linker: ether, thioether, carboxamide, thiourea, sulfonamide, urea, urethane, hydrazine, alkyl, aryl, heteroaryl, alkoxy, cycloalkyl and amine moieties. Examples of L include substituted or unsubstituted polymethylene, arylene, alkylarylene, arylenealkyl, or arylthio.

[0086] Any combination of linkers may be used to attach the reactive functional groups and

10 the haptens together, typically a compound of the present invention when attached to more than one reactive functional group will have one or two linkers attached that may be the same or different. The linker may also be substituted to alter the physical properties of the present compounds, such as solubility and spectral properties of the compound.

III. B. iii) Methods of Making the PI, NRTI or EI Met-Sensitive Moieties

15 [0087] The compounds of the invention are synthesized by an appropriate combination of generally well known synthetic methods. Techniques useful in synthesizing the compounds of the invention are both readily apparent and accessible to those of skill in the relevant art. Methods of synthesizing some of the compounds of the invention are provided in the Examples section.

III. B. iv) Methods of Making the PI, NRTI or EI Derivatives

20 [0088] The compounds of the invention are synthesized by an appropriate combination of generally well known synthetic methods. Techniques useful in synthesizing the compounds of the invention are both readily apparent and accessible to those of skill in the relevant art. Methods of synthesizing some of the compounds of the invention are provided in the

25 Examples section.

IV. Reactive Partners

[0089] The haptens comprising met-sensitive moieties or NNRTI Derivatives can be attached to one or more of a series of compounds known as reactive partners. The reactive partner can be an immunogenic carrier, a non-isotopic signal generating moiety, a solid

30 support, one of a few miscellaneous types, or combinations thereof. It is possible for a compound to be a member of more than one reactive partner category. For example, an

enzyme may be both a non-isotopic signal generating moiety, as well as an immunogenic carrier.

IV. A. Immunogenic Carriers: Creation of Immunogens or Met-Sensitive Antigens or PI Derivative or NRTI Derivative or EI Derivative Antigens

- 5 [0090] The haptens comprising met-sensitive moieties or PI Derivative or NRTI Derivative or EI Derivative can be made immunogenic by coupling them to a suitable immunogenic carrier. This coupling produces a compound alternatively known as an immunogen, an antigen, a Met-Sensitive Antigen, or PI Derivative or NRTI Derivative or EI Derivative Antigen.
- 10 [0091] The immunogenic carrier may be attached to the compounds of the invention either directly through the met-sensitive moiety or PI Derivative or NRTI Derivative or EI Derivative, or through a reactive functional group, if present, or through a non-isotopic signal generating moiety, if present.
- [0092] An immunogenic carrier is a group which, when conjugated to a met-sensitive
15 moiety or PI Derivative or NRTI Derivative or EI Derivative and injected into a mammal, will induce an immune response and elicit the production of antibodies that bind to the corresponding PI or NNRTI. Immunogenic carriers are also referred to as antigenic carriers and by other synonyms common in the art.
- [0093] The molecular weight of immunogenic carriers typically range from about 2,000 to
20 10^7 , usually from about 20,060 to 600,000, and more usually from about 25,000 to 250,000 molecular weight. There will usually be at least about one met-sensitive moiety or PI Derivative or NRTI Derivative or EI Derivative per 150,000 molecular weight, more usually at least one group per 50,000 molecular weight, preferably at least one group per 25,000 molecular weight.
- 25 [0094] Various protein types may be employed as the poly (amino acid) immunogenic carrier. These types include albumins, serum proteins, *e.g.*, globulins, ocular lens proteins, lipoproteins, etc. Illustrative proteins include bovine serum albumin (BSA), keyhole limpet hemocyanin (KLH), egg ovalbumin, bovine gamma-globulin (BGG), etc. Alternatively, synthetic poly(amino acids) may be utilized.
- 30 [0095] The immunogenic carrier can also be a polysaccharide, which is a high molecular weight polymer built up by repeated condensations of monosaccharides. Examples of polysaccharides are starches, glycogen, cellulose, carbohydrate gums, such as gum arabic,

agar, and so forth. The polysaccharide can also contain polyamino acid residues and/or lipid residues.

[0096] The immunogenic carrier can also be a poly(nucleic acid) either alone or conjugated to one of the above mentioned poly(amino acids) or polysaccharides.

5 [0097] The immunogenic carrier can also be a particle. The particles are generally at least about 0.02 microns and not more than about 100 microns, usually at least about 0.05 microns and less than about 20 microns, preferably from about 0.3 to 10 microns diameter. The particle may be organic or inorganic, swellable or non-swellable, porous or non-porous, preferably of a density approximating water, generally from about 0.7 to 1.5 g/mL, and
10 composed of material that can be transparent, partially transparent, or opaque. The particles can be biological materials such as cells and microorganisms, *e.g.*, erythrocytes, leukocytes, lymphocytes, hybridomas, *Streptococcus*, *Staphylococcus aureus*, *E. coli*, viruses, and the like. The particles can also comprise organic and inorganic polymers, liposomes, latex particles, phospholipid vesicles, chylomicrons, lipoproteins, and the like.

15 [0098] The polymers can be either addition or condensation polymers. Particles derived therefrom will be readily dispersible in an aqueous medium and may be adsorptive or functionalizable so as to bind (conjugate) to a met-sensitive moiety or PI Derivative or NRTI Derivative or EI Derivative of the invention.

[0099] The particles can be derived from naturally occurring materials, naturally occurring
20 materials which are synthetically modified, and synthetic materials. Among organic polymers of particular interest are polysaccharides, particularly cross-linked polysaccharides, such as agarose, which is available as Sepharose, dextran, available as Sephadex and Sephacryl, cellulose, starch, and the like; addition polymers, such as polystyrene, polyvinyl alcohol, homopolymers and copolymers of derivatives of acrylate and methacrylate,
25 particularly esters and amides having free hydroxyl functionalities, and the like.

[0100] The particles will usually be polyfunctional and will be bound to or be capable of binding (being conjugated) to a met-sensitive moiety or PI Derivative or NRTI Derivative or EI Derivative. Descriptions of the binding of the particles to the met-sensitive moieties or PI Derivatives or NRTI Derivatives or EI Derivatives are provided in Section III.

IV. B. Non-Isotopic Signal Generating Moiety

[0101] In the methods and compositions of this invention, a variety of signal-generating moieties can be employed. Among these moieties are fluorophores, chemiluminescent compounds, enzymes, inorganic particles, magnetic beads, and colloidal gold. The non-isotopic signal generating moieties discussed herein can be attached to the haptens comprising the met-sensitive moieties or PI Derivatives or NRTI Derivatives or EI Derivatives according to the methods described in Section III and Example 23-26. One of skill in the art would appreciate that non-isotopic signal generating moieties appropriate for the invention but not explicitly referenced in this document can be found in a textbooks or catalogs, such as *Handbook of Fluorescent Probes and Research Products*, 9th ed., Richard Haugland, ed. (Molecular Probes, 2003), which is herein incorporated by reference. Chapter 7 of the *Handbook* is especially useful for selecting non-isotopic signal generating moieties that are appropriate for use in the invention.

[0102] The non-isotopic signal-generating moiety may be attached to the compounds of the invention either directly through the met-sensitive moiety or PI Derivative or NRTI Derivative or EI Derivative, or through a reactive functional group, if present, or through an immunogenic carrier, if present. Non-isotopic signal generating moieties may also be attached to receptors of the invention, as described elsewhere herein. Finally, the non-isotopic signal generating moieties discussed herein can be utilized in the immunoassays and kits of the invention.

IV. B. i) Fluorophores

[0103] For the purposes of the invention a fluorophore can be a substance which itself fluoresces, can be made to fluoresce, or can be a fluorescent analogue of an analyte.

[0104] In principle, any fluorophore can be used in the assays of this invention. Preferred fluorophores, however, have the following characteristics:

- a. A fluorescence lifetime of greater than about 15 nsec;
- b. An excitation wavelength of greater than about 350 nm;
- c. A Stokes shift (a shift to lower wave-length of the emission relative to absorption) of greater than about 20 nm;
- d. For homogeneous assays, fluorescence lifetime should vary with binding status; and
- e. The absorptivity and quantum yield of the fluorophore should be high.

[0105] The longer lifetime is advantageous because it is easier to measure and more easily distinguishable from the Raleigh scattering (background). Excitation wavelengths greater than 350 nm reduce background interference because most fluorescent substances responsible for background fluorescence in biological samples are excited below 350 nm. A greater
5 Stokes shift also allows for less background interference.

[0106] The fluorophore should have a functional group available for conjugation either directly or indirectly to the Met-Sensitive antigen, PI Derivative antigen or NRTI Derivative antigen or EI Derivative antigen, or receptor. An additional criterion in selecting the fluorophore is the stability of the fluorophore: it should not be photophysically unstable, and
10 it should be relatively insensitive to the assay conditions, *e.g.*, pH, polarity, temperature and ionic strength.

[0107] Preferably (though not necessarily), fluorophores for use in heterogenous assays are relatively insensitive to binding status. In contrast, fluorophores for use in homogeneous assay must be sensitive to binding status, *i.e.*, the fluorescence lifetime must be alterable by
15 binding so that bound and free forms can be distinguished.

[0108] Examples of fluorophores useful in the invention are naphthalene derivatives (*e.g.* dansyl chloride), anthracene derivatives (*e.g.* N-hydroxysuccinimide ester of anthracene propionate), pyrene derivatives (*e.g.* N-hydroxysuccinimide ester of pyrene butyrate), fluorescein derivatives (*e.g.* fluorescein isothiocyanate), rhodamine derivatives (*e.g.*
20 rhodamine isothiocyanate), phycoerythrin, and Texas Red.

IV. B. ii) Enzymes

[0109] In an exemplary embodiment, the non-isotopic signal generating moiety is an enzyme. From the standpoint of operability, a very wide variety of enzymes can be used. But, as a practical matter, some enzymes have characteristics which make them preferred
25 over others. The enzyme should be stable when stored for a period of at least three months, and preferably at least six months at temperatures which are convenient to store in the laboratory, normally -20 °C or above. The enzyme should also have a satisfactory turnover rate at or near the pH optimum for binding to the receptor, this is normally at about pH 6-10, usually 6.0 to 8.0. A product should be either formed or destroyed as a result of the enzyme
30 reaction which absorbs light in the ultraviolet region or the visible region, that is the range of about 250-750 nm., preferably 300-600 nm. The enzyme also should have a substrate (including cofactors) which has a molecular weight in excess of 300, preferably in excess of

500, there being no upper limit. The enzyme which is employed or other enzymes, with like activity, will not be present in the sample to be measured, or can be easily removed or deactivated prior to the addition of the assay reagents. Also, there should not be naturally occurring inhibitors for the enzyme present in fluids to be assayed.

5 [0110] Also, although enzymes of up to 600,000 molecular weight can be employed, usually relatively low molecular weight enzymes will be employed of from 10,000 to 300,000 molecular weight, more usually from about 10,000 to 150,000 molecular weight, and frequently from 10,000 to 100,000 molecular weight. Where an enzyme has a plurality of subunits the molecular weight limitations refer to the enzyme and not to the subunits.

10 [0111] For synthetic convenience, it is preferable that there be a reasonable number of groups to which the met-sensitive antigen, PI Derivative antigen or NRTI Derivative antigen or EI Derivative antigen, or receptor may be bonded, particularly amino groups. However, other groups to which the met-sensitive antigen, PI Derivative or NRTI Derivative or antibody may be bonded include hydroxyl groups, thiols, and activated aromatic rings, *e.g.*,
15 phenolic.

[0112] Finally, for the purposes of this invention, the enzymes should be capable of specific labeling so as to be useful in the subject assays. Specific labeling means attachment at a site related to the active site of the enzyme, so that upon binding of the receptor (met-sensitive antigen, PI Derivative antigen or NRTI Derivative antigen or EI Derivative antigen
20 or receptor, depending on the specific immunoassay) to the ligand (again, either the met-sensitive antigen, PI Derivative antigen, NRTI Derivative antigen, EI Derivative antigen, or receptors), the enzyme is satisfactorily enhanced or inhibited.

[0113] Based on these criteria, the following enzymes can be used in the invention: alkaline phosphatase, horseradish peroxidase, lysozyme, glucose-6-phosphate dehydrogenase, lactate dehydrogenase, β -galactosidase, and urease. Also, a genetically engineered fragment
25 of an enzyme may be used, such as the donor and acceptor fragment of β -galactosidase utilized in CEDIA immunoassays (see Henderson DR *et al.* *Clin Chem.* 32(9):1637-1641 (1986)); U.S. Pat. No. 4,708,929. These and other enzymes which can be used have been discussed in detail by Eva Engvall in Enzyme Immunoassay ELISA and EMIT in Methods in
30 Enzymology, 70:419-439 (1980) and in U.S. Pat. No. 4,857,453.

[0114] Enzymes, enzyme fragments, enzyme inhibitors, enzyme substrates, and other components of enzyme reaction systems can be attached to the haptens and receptors, and employed in the immunoassays of the invention. Where any of these components is used as a non-isotopic signal generating moiety, a chemical reaction involving one of the components is part of the signal producing system.

[0115] Coupled catalysts can also involve an enzyme with a non-enzymatic catalyst. The enzyme can produce a reactant, which undergoes a reaction catalyzed by the non-enzymatic catalyst or the non-enzymatic catalyst may produce a substrate (includes coenzymes) for the enzyme. A wide variety of non-enzymatic catalysts, which may be employed are found in U.S. Pat. No. 4,160,645 (1979), the appropriate portions of which are incorporated herein by reference.

[0116] The enzyme or coenzyme employed provides the desired amplification by producing a product which absorbs light, *e.g.*, a dye, or emits light upon irradiation, *e.g.*, a fluorescer. Alternatively, the catalytic reaction can lead to direct light emission, *e.g.*, chemiluminescence. A large number of enzymes and coenzymes for providing such products are indicated in U.S. Pat. No. 4,275,149, columns 19 to 23, and U.S. Pat. No. 4,318,980, columns 10 to 14, which disclosures are incorporated herein by reference.

[0117] A number of enzyme combinations are set forth in U.S. Pat. No. 4,275,149, columns 23 to 28, which combinations can find use in the subject invention. This disclosure is incorporated herein by reference.

[0118] When a single enzyme is used as a label, such enzymes that may find use are hydrolases, transferases, lyases, isomerases, ligases or synthetases and oxidoreductases. In an exemplary embodiment, the enzyme is a hydrolase. Alternatively, luciferases may be used such as firefly luciferase and bacterial luciferase. Illustrative dehydrogenases include malate dehydrogenase, glucose-6-phosphate dehydrogenase, and lactate dehydrogenase. Illustrative oxidases include glucose oxidase. Of the peroxidases, horse radish peroxidase is illustrative. Of the hydrolases, alkaline phosphatase, β -glucosidase and lysozyme are illustrative.

[0119] Of particular interest are enzymes which involve the production of hydrogen peroxide and the use of the hydrogen peroxide to oxidize a dye precursor to a dye. Particular combinations include saccharide oxidases, *e.g.*, glucose and galactose oxidase, or heterocyclic oxidases, such as uricase and xanthine oxidase, coupled with an enzyme which employs the hydrogen peroxide to oxidize a dye precursor, that is, a peroxidase such as horse

radish peroxidase, lactoperoxidase, or microperoxidase. Additional enzyme combinations may be found in the subject matter incorporated by reference.

[0120] Those enzymes, which employ nicotinamide adenine dinucleotide (NAD) or its phosphate (NADP) as a cofactor, particularly the former, can be used. One preferred enzyme is glucose-6-phosphate dehydrogenase, preferably, NAD-dependent glucose-6-phosphate dehydrogenase.

IV. B. iii) Colloidal Gold

[0121] In an exemplary embodiment, the hapten-reactive partner conjugates, as well as the receptors of the invention can comprise a colloidal gold moiety. The immunoassays of the invention can also comprise a colloidal gold moiety. A colloidal gold moiety may possess any chosen size from 1-250 nm. This gold probe detection system, when incubated with a specific target, such as in an immunoassay, will reveal the target through the visibility of the gold particles themselves. The gold particles can be detected by a variety of methods, such as by microscope or eye. Visibility can be enhanced through a short and simple silver enhancing procedure. For detection by eye, gold particles will also reveal immobilized protein on a solid phase such as a blotting membrane through the accumulated red color of the gold. Silver enhancement of this gold precipitate also gives further sensitivity of detection. Further information about colloidal gold can be found in *Handbook of Fluorescent Probes and Research Products*, 9th ed., Richard Haugland, ed. (Molecular Probes, 2003), specifically in chapter 7, p. 251-254.

IV. C. Solid Support

[0122] In an exemplary embodiment, a reactive partner for the compounds of the invention is a solid support. The solid support may be attached to the compound either directly through the met-sensitive moiety or PI Derivative or NRTI Derivative or EI Derivative, or through the reactive functional group, if present, or through an immunogenic carrier molecule, if present. Even if a reactive functional group and/or an immunogenic carrier are present, the solid support may be attached through the met-sensitive moiety, PI Derivative or NRTI Derivative or EI Derivative.

[0123] A solid support suitable for use in the present invention is typically substantially insoluble in liquid phases. Solid supports of the current invention are not limited to a specific type of support. Rather, a large number of supports are available and are known to one of ordinary skill in the art. Thus, useful solid supports include semi-solids, such as aerogels and

hydrogels, resins, beads, biochips (including thin film coated biochips), multi-well plates (also referred to as microtiter plates), membranes, conducting and nonconducting metals and magnetic supports. More specific examples of useful solid supports include silica gels, polymeric membranes, particles, derivatized plastic films, glass beads, cotton, plastic beads, alumina gels, polysaccharides such as Sepharose, poly(acrylate), polystyrene, poly(acrylamide), polyol, agarose, agar, cellulose, dextran, starch, FICOLL, heparin, glycogen, amylopectin, mannan, inulin, nitrocellulose, diazocellulose, polyvinylchloride, polypropylene, polyethylene (including poly(ethylene glycol)), nylon, latex bead, magnetic bead, paramagnetic bead, superparamagnetic bead, starch and the like.

[0124] In some embodiments, the solid support may include a solid support reactive functional group, including, but not limited to, hydroxyl, carboxyl, amino, thiol, aldehyde, halogen, nitro, cyano, amido, urea, carbonate, carbamate, isocyanate, sulfone, sulfonate, sulfonamide, sulfoxide, etc., for attaching the compounds of the invention. Useful reactive groups are disclosed below and are equally applicable to the solid support reactive functional groups herein.

[0125] A suitable solid phase support can be selected on the basis of desired end use and suitability for various synthetic protocols. For example, where amide bond formation is desirable to attach the compounds of the invention to the solid support, resins generally useful in peptide synthesis may be employed, such as polystyrene (*e.g.*, PAM-resin obtained from Bachem Inc., Peninsula Laboratories, etc.), POLYHIPE™ resin (obtained from Aminotech, Canada), polyamide resin (obtained from Peninsula Laboratories), polystyrene resin grafted with polyethylene glycol (TentaGel™, Rapp Polymere, Tubingen, Germany), polydimethyl-acrylamide resin (available from Milligen/Bioscience, California), or PEGA beads (obtained from Polymer Laboratories).

IV. D. Miscellaneous

[0126] Miscellaneous reactive partners of the invention include a polypeptide, polysaccharide, a synthetic polymer, and combinations thereof.

IV. E. Methods of Attaching a Hapten to a Reactive Partner

[0127] There are many options available for the conjugation of a hapten comprising a metal-sensitive moiety or a PI Derivative or NRTI Derivative or EI Derivative with a reactive partner. In an exemplary embodiment, the hapten comprises a reactive functional group, and is conjugated to the reactive partner. An illustration of this strategy is provided in Example

40 and 43. In another exemplary embodiment, the reactive partner is activated, and then conjugated to the compound comprising the met-sensitive moiety. Illustrations of this strategy are provided in Examples 41 and 42. These conjugations produce a hapten-reactive partner conjugate.

- 5 **[0128]** The methods of attaching are dependent upon the reactive groups present at the site of activation. In an exemplary embodiment, the reactive functional group of the haptens of the invention and the functional group of the reactive part comprise electrophiles and nucleophiles that can generate a covalent linkage between them. Alternatively, the reactive functional group comprises a photoactivatable group, which becomes chemically reactive
- 10 only after illumination with light of an appropriate wavelength. Typically, the conjugation reaction between the reactive functional group and the reactive partner results in one or more atoms of the reactive functional group or the reactive partner being incorporated into a new linkage attaching the hapten to the reactive partner. Selected examples of functional groups and linkages are shown in Table 1, where the reaction of an electrophilic group and a
- 15 nucleophilic group yields a covalent linkage.

Table 1: Examples of some routes to useful covalent linkages with electrophile and nucleophile reactive groups

Electrophilic Group	Nucleophilic Group	Resulting Covalent Linkage
activated esters*	amines/anilines	carboxamides
acyl azides**	amines/anilines	carboxamides
acyl halides	amines/anilines	carboxamides
acyl halides	alcohols/phenols	esters
acyl nitriles	alcohols/phenols	esters
acyl nitriles	amines/anilines	carboxamides
aldehydes	amines/anilines	imines
aldehydes or ketones	hydrazines	hydrazones
aldehydes or ketones	hydroxylamines	oximes
alkyl halides	amines/anilines	alkyl amines
alkyl halides	carboxylic acids	esters
alkyl halides	thiols	thioethers
alkyl halides	alcohols/phenols	ethers
alkyl sulfonates	thiols	thioethers

alkyl sulfonates	carboxylic acids	esters
alkyl sulfonates	alcohols/phenols	ethers
anhydrides	alcohols/phenols	esters
anhydrides	amines/anilines	carboxamides
aryl halides	thiols	thiophenols
aryl halides	amines	aryl amines
aziridines	thiols	thioethers
boronates	glycols	boronate esters
carboxylic acids	amines/anilines	carboxamides
carboxylic acids	alcohols	esters
carboxylic acids	hydrazines	hydrazides
carbodiimides	carboxylic acids	N-acylureas or anhydrides
diazoalkanes	carboxylic acids	esters
epoxides	thiols	thioethers
haloacetamides	thiols	thioethers
halotriazines	amines/anilines	aminotriazines
halotriazines	alcohols/phenols	triazinyl ethers
imido esters	amines/anilines	amidines
isocyanates	amines/anilines	ureas
isocyanates	alcohols/phenols	urethanes
isothiocyanates	amines/anilines	thioureas
maleimides	thiols	thioethers
phosphoramidites	alcohols	phosphite esters
silyl halides	alcohols	silyl ethers
sulfonate esters	amines/anilines	alkyl amines
sulfonate esters	thiols	thioethers
sulfonate esters	carboxylic acids	esters
sulfonate esters	alcohols	ethers
sulfonyl halides	amines/anilines	sulfonamides
sulfonyl halides	phenols/alcohols	sulfonate esters

* Activated esters, as understood in the art, generally have the formula $-\text{CO}\Omega$, where Ω is a good leaving group (*e.g.* oxysuccinimidyl ($-\text{OC}_4\text{H}_4\text{O}_2$) oxysulfosuccinimidyl ($-\text{OC}_4\text{H}_3\text{O}_2-\text{SO}_3\text{H}$), -1-oxybenzotriazolyl ($-\text{OC}_6\text{H}_4\text{N}_3$); or an aryloxy group or aryloxy substituted one

or more times by electron withdrawing substituents such as nitro, fluoro, chloro, cyano, or trifluoromethyl, or combinations thereof, used to form activated aryl esters; or a carboxylic acid activated by a carbodiimide to form an anhydride or mixed anhydride $-\text{OCOR}^a$ or $-\text{OCNR}^a\text{NHR}^b$, where R^a and R^b , which may be the same or different, are $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ perfluoroalkyl, or $\text{C}_1\text{-C}_6$ alkoxy; or cyclohexyl, 3-dimethylaminopropyl, or N-morpholinoethyl).

** Acyl azides can also rearrange to isocyanates

[0129] Where the reactive functional group is an activated ester of a carboxylic acid, such as a succinimidyl ester of a carboxylic acid, the resulting compound is particularly useful for preparing conjugates of carrier molecules such as proteins, nucleotides, oligonucleotides, or haptens. Where the reactive group is a maleimide or haloacetamide the resulting compound is particularly useful for conjugation to thiol-containing substances. Where the reactive group is a hydrazide, the resulting compound is particularly useful for conjugation to periodate-oxidized carbohydrates and glycoproteins, and in addition is an aldehyde-fixable polar tracer for cell microinjection. Where the reactive group is a silyl halide, the resulting compound is particularly useful for conjugation to silica surfaces, particularly where the silica surface is incorporated into a fiber optic probe subsequently used for remote ion detection or quantitation.

[0130] In order to conjugate haptens comprising met-sensitive moieties or PI Derivatives or NRTI Derivatives or EI Derivatives to a reactive partner, the haptens comprising the met-sensitive moieties, PI Derivatives and NRTI Derivatives and EI Derivatives are typically first dissolved in water or a water-miscible such as a lower alcohol, dimethylformamide (DMF), dimethylsulfoxide (DMSO), acetone, acetonitrile, tetrahydrofuran (THF), dioxane or acetonitrile. These methods are been described in detail in Hermanson Greg T., Bioconjugate Techniques, Chapter 9, p. 419-455, Academic Press, Inc., 1996, which is incorporated herein by reference. Conjugates typically result from mixing appropriate reactive compounds and the component to be conjugated in a suitable solvent in which both are soluble, using methods well known in the art, followed by separation of the conjugate from any unreacted component and by-products. These present compounds are typically combined with the component under conditions of concentration, stoichiometry, pH, temperature and other factors that affect chemical reactions that are determined by both the reactive groups on the compound and the expected site of modification on the component to be modified. These factors are generally well known in the art of forming bioconjugates (Haugland *et al.*, "Coupling of Antibodies with Biotin", The Protein Protocols Handbook, J.M. Walker, ed.,

Humana Press, (1996); Haugland "Coupling of Monoclonal Antibodies with Fluorophores", Methods in Molecular Biology, Vol. 45: Monoclonal Antibody Protocols, W.C. Davis, ed. (1995)). For those reactive compounds that are photoactivated, conjugation requires illumination of the reaction mixture to activate the reactive compound. The labeled component is used in solution or lyophilized and stored for later use.

IV. E. i) Methods of Attaching a Colloidal Gold Moiety

[0131] The conjugation of selected proteins to gold particles depends upon at least three physical phenomena. The first is the charge attraction of the negative gold particle to positively charged protein, receptor, solid support, or hapten. The second is the hydrophobic absorption of the protein, receptor, solid support, or hapten to the gold particle surface. The third is the binding of the gold to sulphur (dative binding) where this may exist within the structure of the protein, receptor, solid support, or hapten.

V. Receptors

V. A. Introduction

[0132] Included within the invention are receptors specific for the Met-Sensitive Moieties or PI Derivatives or NRTI Derivatives or EI Derivatives described within. Also included within the invention are receptors that substantially compete with the binding of the receptors specific for the Met-Sensitive Moieties or PI Derivatives or NRTI Derivatives or EI Derivatives described within. In an exemplary embodiment, the receptor is an antibody. In another exemplary embodiment, the receptor comprises the antigen-binding residues of an antibody. In another exemplary embodiment, the receptor can further comprise a non-isotopic signal generating moiety as discussed herein. The methods of attaching the non-isotopic signal generating moieties to the haptens of the invention are applicable to the methods of attaching the non-isotopic signal generating moieties to the receptors of the invention.

V. B. Antibodies

[0133] Antibodies, or immunoglobulins, are molecules produced by organs of the immune system to defend against antigens. The basic antibody structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The carboxy-terminal portion of each

chain defines a constant region primarily responsible for effector function. Human light chains are classified as kappa and lambda light chains. Heavy chains are classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. Within light and heavy chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 10 more amino acids. See generally, Cellular and Molecular Immunology Ch. 3 (Abbas and Lichtman, ed., 5th ed. Saunders (2003)) (incorporated by reference in its entirety for all purposes). The variable regions of each light/heavy chain pair form the antibody binding site. Thus, an intact IgG antibody has two binding sites. Except in bifunctional or bispecific antibodies, the two binding sites are the same.

[0134] The chains all exhibit the same general structure of relatively conserved framework regions (FR) joined by three hyper variable regions, also called complementarity determining regions or CDRs. The CDRs from the two chains of each pair are aligned by the framework regions, enabling binding to a specific epitope. From N-terminal to C-terminal, both light and heavy chains comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each domain is in accordance with the definitions of Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk *J. Mol. Biol.* **196**:901-917 (1987); Chothia *et al. Nature* **342**:878-883 (1989).

[0135] Antibodies exist as intact immunoglobulins or as a number of well-characterized fragments. Basic antibody fragments include Fab, which consists of portions of a heavy chain (above the hinge region) and a light chain, and Fab', which is essentially Fab with part of the hinge region attached. Peptidases digest the antibody in different ways to produce fragments with combinations of these basic antibody fragments. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce $F(ab)'_2$, a dimer of Fab which itself is a light chain joined to V_H - C_H1 by a disulfide bond. The $F(ab)'_2$ may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the $F(ab)'_2$ dimer into a Fab' monomer. While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized *de novo* either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments.

V. B. i) Production of Antibodies

[0136] Antibodies specific for the antigens of the invention may be produced by *in vitro* or *in vivo* techniques. *In vitro* techniques involve exposure of lymphocytes to the met-sensitive antigens PI Derivative antigens or NRTI Derivative antigens or EI Derivative antigens, while
5 *in vivo* techniques, such as the production of polyclonal and monoclonal antibodies, require the injection of the met-sensitive antigens or PI Derivative antigens or NRTI Derivative antigens or EI Derivative antigens into a suitable vertebrate host.

[0137] Polyclonal antibody production methods are known to those of skill in the art and can be conducted on suitable vertebrate hosts, including mice, rats, rabbits, sheep, goats, and
10 the like. In an exemplary embodiment, an inbred strain of mice (*e.g.*, BALB/C mice) or rabbits is injected with the met-sensitive antigen or PI Derivative antigen or NRTI Derivative antigen or EI Derivative antigen using a standard adjuvant, such as Freund's adjuvant, according to a standard immunization protocol. The injections may be made intramuscularly, intraperitoneally, subcutaneously, or the like. The animal's immune response to the met-
15 sensitive antigen or PI Derivative antigen or NRTI Derivative antigen or EI Derivative antigen preparation is monitored by taking test bleeds and determining the titer of reactivity to the met-sensitive antigen or PI Derivative antigen or NRTI Derivative antigen or EI Derivative antigen respectively. When appropriately high titers of antibody to the met-sensitive antigen or PI Derivative antigen or NRTI Derivative antigen or EI Derivative
20 antigen are obtained, blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the met-sensitive antigen or PI Derivative antigen or NRTI Derivative antigen or EI Derivative antigen or anti-HIV therapeutic can be done if desired (*see*, Harlow & Lane, *supra*).

[0138] Monoclonal antibodies may be obtained by various techniques familiar to those
25 skilled in the art. Briefly, spleen cells from an animal injected with a met-sensitive antigen or PI Derivative antigen or NRTI Derivative antigen or EI Derivative antigen are immortalized, commonly by fusion with a myeloma cell (*see*, Kohler & Milstein, *Eur. J. Immunol.* **6**:511-519 (1976)). Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods well known in the art. Colonies
30 arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the met-sensitive antigen or PI Derivative antigen or NRTI Derivative antigen or EI Derivative antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal

cavity of a vertebrate host. Alternatively, one may isolate DNA sequences which encode a monoclonal antibody or a binding fragment thereof by screening a DNA library from human B cells according to the general protocol outlined by Huse, *et al.*, *Science* **246**:1275-1281 (1989).

5 ***V. B. ii) Screening for Antibodies***

[0139] Monoclonal antibodies and polyclonal sera are collected and titered against the met-sensitive antigens or PI Derivative antigens or NRTI Derivative antigens or EI Derivative antigens of the invention in an immunoassay, which is described in Section VI below.

Specifically, for monoclonal antibodies the selection methods are divided into a primary and
10 secondary screening method. In the case of polyclonal sera only the secondary screening method is used.

[0140] The primary screening method is a reverse ELISA procedure which was set up such that the monoclonal antibody is bound on the Enzyme Immunoassay (EIA) plate by rabbit anti-mouse Ig serum, and positive wells are selected by their ability to bind hapten-reactive
15 partner conjugates comprising the met-sensitive moiety or PI Derivative or NRTI Derivative or EI Derivative of interest. Positives from these primary screens were transferred to 24-well plates, allowed to grow for several days, then were screened by a competition reverse ELISA, wherein the hapten-reactive partner conjugates must compete with free drug *i.e.*, lopinavir, for antibody binding sites. If the activity from the non-isotopic signal generating moiety
20 measured when free drug was present was less than that seen when only hapten-reactive partner conjugates is present, then the antibody preferentially binds the free drug over the hapten-reactive partner conjugates form. Antibodies from these wells were cloned by serial dilution, with cloning plates screened by reverse ELISA.

[0141] The secondary screening procedure is used for both polyclonal and monoclonal
25 antibody testing which involved taking selected antibodies and further testing them on a Cobas Bio Analyzer for inhibition of hapten-reactive partner conjugates, dose-response and cross-reactivity with various free drug solutions in the homogeneous enzyme immunoassay configuration. In the case of monoclonal antibodies, wells that produced a positive response in the assay comprising the non-isotopic signal generating moiety plus a negative response
30 when tested in the presence of anti-HIV therapeutic were selected for further testing. The secondary screening method involves testing the degree of antibody inhibition of hapten-reactive partner conjugate, parent drug binding and cross-reactivity properties in a

homogeneous assay format which simulates an assay protocol that may be used in the final kitted product. For example, instrument parameters, reagent preparation, and nonlinear data handling analysis is used. If adequate inhibition is obtained the antibody modulation property is measured in the presence of varying concentrations of anti-HIV therapeutic. Anti-HIV therapeutic standards and controls are prepared by adding known amounts of anti-HIV therapeutic to a buffered synthetic matrix. Cross-reactivity testing is performed by adding known amounts of cross reactant into human serum. The instrument used for this evaluation is the Roche Cobas Mira Chemistry Analyzer. A homogeneous enzyme immunoassay technique which can be used for the analysis is based on competition between a drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for receptor binding sites. Enzyme activity decreases upon binding to the antibody, so the drug concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that is measured spectrophotometrically. Endogenous serum G6PDH does not interfere because the coenzyme functions only with the bacterial (*Leuconostoc mesenteroides*) enzyme employed in the assay. The quantitative analysis of drugs can be performed using human urine, serum, plasma, whole blood, or ultra filtrate.

V. C. Other Receptors

[0142] Receptors can comprise the antigen-binding domains or amino acids critical for antigen binding, *e.g.* antigen-binding residues, of an antibody that specifically binds the Met-Sensitive Moieties or PI Derivatives or NRTI Derivatives or EI Derivatives. Such antigen-binding domains or residues can comprise the Complementarity-Determining Region (CDR) of an antibody. The receptors can also structurally mimic the structure represented by the antigen-binding domains or residues of a CDR. For example, if there are four amino acids within the CDR of an antibody that are critical for binding the antigen to the antibody, *e.g.* antigen-binding residues, then a receptor of the invention need only possess those four critical amino acids structurally arranged so as to substantially mimic their structural arrangement within the CDR of the antibody. The linkages between the critical amino acids are only important to the extent that they structurally mimic the CDR of the antibody. In this example, substitution of isosteres of the critical amino acids, such as aspartic acid for glutamic acid, are allowed.

[0143] Once the specific receptors against the met-sensitive moiety or PI Derivative or NRTI Derivative or EI Derivative are available, the following immunoassay methods can be employed.

VI. Immunoassays

VI. A. Introduction

[0144] In the TDM field there are several categories of methods available for determining the presence or the concentration of met-sensitive moieties PI Derivatives or NRTI Derivatives or EI Derivatives in a sample. One such category is immunoassays, which are currently used to determine the presence or concentration of various analytes in biological samples, both conveniently and reliably (The Immunoassay Handbook, edited by David Wild, M Stockton Press, 1994). Generally speaking, immunoassays utilize specific receptors to target analytes in fluids, where at least one such receptor is generally labeled with one of a variety of non-isotopic signal-generating moieties.

[0145] Immunoassays usually are classified in one of several ways. One method is according to the mode of detection used, *i.e.*, enzyme immunoassays, radio immunoassays, fluorescence polarization immunoassays, chemiluminescence immunoassays, turbidimetric assays, etc. Another grouping method is according to the assay procedure used, *i.e.*, competitive assay formats, sandwich-type assay formats as well as assays based on precipitation or agglutination principles. In the instant application, a further distinction is made depending on whether washing steps are included in the procedure (so-called heterogeneous assays) or whether reaction and detection are performed without a washing step (so-called homogeneous assays). All the essential terms, procedures and devices are known to the skilled artisan from text books in the field, *e.g.*, "Manual of Immunological Methods", eds. P. Brousseau and M. Beaudet, CRC Press, 1998, and "Practice and Theory of Enzyme Immunoassays", eds. P. Tijssen and R.H. Burdon, Elsevier Health Sciences, 1985, are herewith included by reference.

VI. B. Homogeneous and Heterogeneous Immunoassays

[0146] As mentioned above, immunoassays may be heterogeneous or homogeneous. Heterogeneous immunoassays have been applied to both small and large molecular weight analytes and require separation of bound materials (to be detected or determined) from free materials (which may interfere with that determination). Heterogeneous immunoassays may comprise a receptor or an antigen immobilized on solid surfaces such as plastic microtiter

plates, beads, tubes, or the like or on membrane sheets, chips and pieces of glass, nylon, cellulose or the like ("Immobilized Enzymes, Antigens, Antibodies, and Peptides", ed. Howard H. Weetall, Marcel Dekker, Inc., 1975). In heterogeneous immunoassays, antigen-receptor complexes bound to the solid phase are separated from unreacted and non-specific analyte in solution, generally by centrifugation, filtration, precipitation, magnetic separation or aspiration of fluids from solid phases, followed by repeated washing of the solid phase bound antigen-receptor complex.

[0147] Homogeneous assays are, in general, liquid phase procedures that do not utilize antigens or receptors that are immobilized on solid materials. Separation and washing steps are not required. In an exemplary embodiment, the antigens or receptors comprise a fluorophore signal-generating moiety, which upon binding of the antigen or receptor with a target analyte undergoes an excitation or quenching of fluorescence emissions, due to the close steric proximity of the binding pair. In another exemplary embodiment, the antigens or receptors comprise an enzyme signal-generating moiety, which upon binding of the antigen or receptor with a target analyte undergoes an enhancement or a reduction in enzyme product formation, due to a conformational change which occurs in the enzyme upon analyte binding. Homogeneous methods have typically been developed for the detection of haptens and small molecules, such as drugs, hormones and peptides.

VI. C. Non-Isotopic Signal-Generating Moieties used in Immunoassays

[0148] In the methods and compositions of this application, a variety of signal-generating moieties can be employed. Among these moieties are fluorophores and enzymes. The fluorophores and enzymes discussed herein can be attached to the haptens comprising the met-sensitive moieties or PI Derivatives or NRTI Derivatives or EI Derivatives according to the methods described elsewhere in this document.

VI. C. i) Fluorophores

[0149] For the purposes of the invention a fluorophore can be a substance which itself fluoresces, can be made to fluoresce, or can be a fluorescent analogue of an analyte.

[0150] In principle, any fluorophore can be used in the assays of this invention. Preferred fluorophores, however, have the following characteristics:

- a. A fluorescence lifetime of greater than about 15 nsec;
- b. An excitation wavelength of greater than about 350 nm;

- c. A Stokes shift (a shift to lower wave-length of the emission relative to absorption) of greater than about 20 nm;
- d. For homogeneous assays, fluorescence lifetime should vary with binding status; and
- e. The absorptivity and quantum yield of the fluorophore should be high.

[0151] The longer lifetime is advantageous because it is easier to measure and more easily distinguishable from the Raleigh scattering (background). Excitation wavelengths greater than 350 nm reduce background interference because most fluorescent substances responsible for background fluorescence in biological samples are excited below 350 nm. A greater Stokes shift also allows for less background interference.

[0152] The fluorophore should have a functional group available for conjugation either directly or indirectly to the Met-Sensitive antigen, PI Derivative antigen or NRTI Derivative antigen or EI Derivative antigen, or receptor. An additional criterion in selecting the fluorophore is the stability of the fluorophore: it should not be photophysically unstable, and it should be relatively insensitive to the assay conditions, *e.g.*, pH, polarity, temperature and ionic strength.

[0153] Preferably (though not necessarily), fluorophores for use in heterogenous assays are relatively insensitive to binding status. In contrast, fluorophores for use in homogeneous assay must be sensitive to binding status, *i.e.*, the fluorescence lifetime must be alterable by binding so that bound and free forms can be distinguished.

[0154] Examples of fluorophores useful in the invention are naphthalene derivatives (*e.g.* dansyl chloride), anthracene derivatives (*e.g.* N-hydroxysuccinimide ester of anthracene propionate), pyrene derivatives (*e.g.* N-hydroxysuccinimide ester of pyrene butyrate), fluorescein derivatives (*e.g.* fluorescein isothiocyanate), rhodamine derivatives (*e.g.* rhodamine isothiocyanate), phycoerythrin, and Texas Red.

VI. C. ii) Enzymes

[0155] In an exemplary embodiment, the signal-generating moiety is an enzyme. From the standpoint of operability, a very wide variety of enzymes can be used. But, as a practical matter, some enzymes have characteristics which make them preferred over others. The enzyme should be stable when stored for a period of at least three months, and preferably at least six months at temperatures which are convenient to store in the laboratory, normally -20 °C or above. The enzyme should also have a satisfactory turnover rate at or near the pH optimum for binding to the receptor, this is normally at about pH 6-10, usually 6.0 to 8.0. A

product should be either formed or destroyed as a result of the enzyme reaction which absorbs light in the ultraviolet region or the visible region, that is the range of about 250-750 nm., preferably 300-600 nm. The enzyme also should have a substrate (including cofactors) which has a molecular weight in excess of 300, preferably in excess of 500, there being no upper limit. The enzyme which is employed or other enzymes, with like activity, will not be present in the sample to be measured, or can be easily removed or deactivated prior to the addition of the assay reagents. Also, there should not be naturally occurring inhibitors for the enzyme present in fluids to be assayed.

[0156] Also, although enzymes of up to 600,000 molecular weight can be employed, usually relatively low molecular weight enzymes will be employed of from 10,000 to 300,000 molecular weight, more usually from about 10,000 to 150,000 molecular weight, and frequently from 10,000 to 100,000 molecular weight. Where an enzyme has a plurality of subunits the molecular weight limitations refer to the enzyme and not to the subunits.

[0157] For synthetic convenience, it is preferable that there be a reasonable number of groups to which the met-sensitive antigen, PI Derivative antigen or NRTI Derivative antigen or EI Derivative antigen, or receptor may be bonded, particularly amino groups. However, other groups to which the met-sensitive antigen, PI Derivative antigen or NRTI Derivative antigen or EI Derivative antigen or antibody may be bonded include hydroxyl groups, thiols, and activated aromatic rings, *e.g.*, phenolic.

[0158] Finally, for the purposes of this invention, the enzymes should be capable of specific labeling so as to be useful in the subject assays. Specific labeling means attachment at a site related to the active site of the enzyme, so that upon binding of the receptor (met-sensitive antigen, PI Derivative antigen or NRTI Derivative antigen or EI Derivative antigen or receptor, depending on the specific immunoassay) to the ligand (again, either the met-sensitive antigen, PI Derivative antigen or NRTI Derivative antigen or EI Derivative antigen, or receptors), the enzyme is satisfactorily enhanced or inhibited.

[0159] Based on these criteria, the following enzymes can be used in the invention: alkaline phosphatase, horseradish peroxidase, lysozyme, glucose-6-phosphate dehydrogenase, lactate dehydrogenase, β -galactosidase, and urease. Also, a genetically engineered fragment of an enzyme may be used, such as the donor and acceptor fragment of β -galactosidase utilized in CEDIA immunoassays (see Henderson DR *et al.* *Clin Chem.* 32(9):1637-1641 (1986)); U.S. Pat. No. 4,708,929. These and other enzymes which can be used have been

discussed in detail by Eva Engvall in Enzyme Immunoassay ELISA and EMIT in Methods in Enzymology, **70**:419-439 (1980) and in U.S. Pat. No. 4,857,453.

[0160] In an exemplary embodiment, the enzyme is glucose-6-phosphate dehydrogenase (G6PDH) and it is attached to a hapten comprising a met-sensitive moiety or PI Derivative or NRTI Derivative or EI Derivative, thus forming a hapten-reactive partner conjugate. In order to select the receptor (such as polyclonal antibodies or monoclonal antibodies) which would best interact in a homogeneous enzyme immunoassay with the hapten comprising a met-sensitive moiety or PI Derivative or NRTI Derivative or EI Derivative, a variety of interrelated factors must be considered. First, the receptor must recognize and affect the activity of the hapten-reactive partner conjugate. Second, in the case of met-sensitive immunoassays, the receptor must be able to differentiate between both metabolized and unmetabolized versions of anti-HIV therapeutic. As several anti-HIV therapeutics are often employed in combination, the receptor should also be selective for one anti-HIV therapeutic over the others.

[0161] The selection procedure will be demonstrated using a hapten-reactive partner conjugate comprising G6PDH as the reactive partner and a met-sensitive moiety of lopinavir as the hapten. The first step in selecting a receptor involves testing the magnitude of receptor inhibition of a hapten-reactive partner conjugate. In this step, the goal is to determine and select for those receptors which significantly inhibit the enzyme activity of G6PDH.

Example 29 presents an illustration of this methodology. Receptors which perform well in the first test are then subjected to a second test. Here, the receptor is first incubated with tipranavir. Next the hapten-reactive partner conjugate is added. An exemplary receptor would preferentially bind to lopinavir instead of the hapten-reactive partner conjugate. The reduction in binding to the hapten-reactive partner conjugate would be visible as an increase G6PDH activity. Example 30 presents an illustration of this methodology.

VI. D. Detection

VI. D. i) Via Fluorescence

[0162] When a fluorescently labeled analyte (either a met-sensitive antigen, PI Derivative antigen or NRTI Derivative antigen or EI Derivative antigen, or receptor) is employed, the fluorescence emitted is proportional (either directly or inversely) to the amount of analyte. The amount of fluorescence is determined by the amplitude of the fluorescence decay curve

for the fluorescent species. This amplitude parameter is directly proportional to the amount of fluorescent species and accordingly to the analyte.

[0163] In general spectroscopic measurement of fluorescence is accomplished by:

- a. exciting the fluorophore with a pulse of light;
- b. detecting and storing an image of the excitation pulse and an image of all the fluorescence (the fluorescent transient) induced by the excitation pulse;
- c. digitizing the image;
- d. calculating the true fluorescent transient from the digitized data;
- e. determining the amplitude of the fluorescent transient as an indication of the amount of fluorescent species.

[0164] According to the method, substantially all of the fluorescence emitted by the fluorescent species reaching the detector as a function of time from the instant of excitation is measured. As a consequence, the signal being detected is a superimposition of several component signals (for example, background and one analyte specific signal). As mentioned, the individual contributions to the overall fluorescence reaching the detector are distinguished based on the different fluorescence decay rates (lifetimes) of signal components. In order to quantitate the magnitude of each contribution, the detected signal data is processed to obtain the amplitude of each component. The amplitude of each component signal is proportional to the concentration of the fluorescent species.

VI. D. ii) Via Enzyme

[0165] Detection of the amount of product produced by the hapten-reactive partner conjugate of the invention can be accomplished by several methods which are known to those of skill in the art. Among these methods are colorimetry, fluorescence, and spectrophotometry. These methods of detection are discussed in "Analytical Biochemistry" by David Holme, Addison-Wesley, 1998, which is incorporated herein by reference.

VI. E. Lateral Flow Chromatography

[0166] The compounds and methods of the invention also encompass the use of these materials in lateral flow chromatography technologies. The essence of lateral flow chromatography involves a membrane strip which comprises a detection device, such as a non-isotopic signal generating moiety, for the anti-HIV therapeutic of interest. A sample from a patient is then applied to the membrane strip. The sample interacts with the detection device, producing a result. The results can signify several things, including the absence of

the anti-HIV therapeutic in the sample, the presence of the anti-HIV therapeutic in the sample, and even the concentration of the anti-HIV therapeutic in the sample.

[0167] In one embodiment, the invention provides a method of qualitatively determining the presence or absence of an anti-HIV therapeutic in a sample, through the use of lateral flow chromatography. The basic design of the qualitative lateral flow device is as follows: 1) The sample pad is where the sample is applied. The sample pad is treated with chemicals such as buffers or salts, which, when redissolved, optimize the chemistry of the sample for reaction with the conjugate, test, and control reagents. 2) Conjugate release pad is typically a polyester or glass fiber material that is treated with a conjugate reagent such as an antibody colloidal gold conjugate. A typical process for treating a conjugate pad is to use impregnation followed by drying. In use, the liquid sample added to the test will redissolve the conjugate so that it will flow into the membrane. 3) The membrane substrate is usually made of nitrocellulose or a similar material whereby antibody capture components are immobilized. 4) A wicking pad is used in tests where blood plasma must be separated from whole blood. An impregnation process is usually used to treat this pad with reagents intended to condition the sample and promote cell separation. 5) The absorbent pad acts as a reservoir for collecting fluids that have flowed through the device. 6) The above layers and membrane system are laminated onto a plastic backing with adhesive material which serves as a structural member.

[0168] In another embodiment, the invention provides a method of qualitatively determining the presence of an anti-HIV therapeutic in a sample, through the use of lateral flow chromatography. In this embodiment, the membrane strip comprises a sample pad, which is a conjugate release pad (CRP) which comprises a receptor that is specific for the anti-HIV therapeutic of interest. This receptor is conjugated to a non-isotopic signal-generating moiety, such as a colloidal gold particle. Other detection moieties useful in a lateral flow chromatography environment include dyes, colored latex particles, fluorescently labeled latex particles, non-isotopic signal generating moieties, etc. The membrane strip further comprises a capture line, in which the met-sensitive moiety or PI Derivative antigen or NRTI Derivative antigen or EI Derivative antigen is immobilized on the strip. In some embodiments, this immobilization is through covalent attachment to the membrane strip, optionally through a linker. In other embodiments, the immobilization is through non-covalent attachment to the membrane strip. In still other embodiments, the immobile met-

sensitive moiety or PI Derivative or NRTI Derivative or EI Derivative in the capture line is attached to a reactive partner, such as an immunogenic carrier like BSA.

[0169] Sample from a patient is applied to the sample pad, where it can combine with the receptor in the CRP, thus forming a solution. This solution is then allowed to migrate chromatographically by capillary action across the membrane. When the anti-HIV therapeutic of interest is present in the sample, an anti-HIV therapeutic-receptor complex is formed, which migrates across the membrane by capillary action. When the solution reaches the capture line, the anti-HIV therapeutic-receptor complex will compete with the immobile anti-HIV therapeutic for the limited binding sites of the receptor. When a sufficient concentration of anti-HIV therapeutic is present in the sample, it will fill the limited receptor binding sites. This will prevent the formation of a colored receptor-immobile anti-HIV therapeutic complex in the capture line. Therefore, absence of color in the capture line indicates the presence of anti-HIV therapeutic in the sample.

[0170] In the absence of anti-HIV therapeutic in the sample, a colored receptor-immobile anti-HIV therapeutic complex will form once the solution reaches the capture line of the membrane strip. The formation of this complex in the capture line is evidence of the absence of anti-HIV therapeutic in the sample.

[0171] In another embodiment, the invention provides a method of quantitatively determining the amount of an anti-HIV therapeutic in a sample, through the use of lateral flow chromatography. This technology is further described in U.S. Pat. No. 4,391,904; 4,435,504; 4,959,324; 5,264,180; 5,340,539; and 5,416,000, among others, which are herein incorporated by reference. In one embodiment, the receptor is immobilized along the entire length of the membrane strip. In general, if the membrane strip is made from paper, the receptor is covalently bound to the membrane strip. If the membrane strip is made from nitrocellulose, then the receptor can be non-covalently attached to the membrane strip through, for example, hydrophobic and electrostatic interactions.

[0172] The membrane strip comprises a CRP which comprises the anti-HIV therapeutic of interest attached to a detector moiety. In an exemplary embodiment, the detector moiety is an enzyme, such as horseradish peroxidase (HRP).

[0173] Sample from a patient is applied to the membrane strip, where it can combine with the anti-HIV/detector molecule in the CRP, thus forming a solution. This solution is then allowed to migrate chromatographically by capillary action across the membrane. When the

anti-HIV therapeutic of interest is present in the sample, both the sample anti-HIV therapeutic and the anti-HIV/detector molecule compete for the limited binding sites of the receptor.

When a sufficient concentration of anti-HIV therapeutic is present in the sample, it will fill the limited receptor binding sites. This will force the anti-HIV/detector molecule to continue

5 to migrate in the membrane strip. The shorter the distance of migration of the anti-HIV/detector molecule in the membrane strip, the lower the concentration of anti-HIV therapeutic in the sample, and vice versa. When the anti-HIV/detector molecule comprises an enzyme, the length of migration of the anti-HIV/detector molecule can be detected by applying an enzyme substrate to the membrane strip. Detection of the product of the enzyme
10 reaction is then utilized to determine the concentration of the anti-HIV therapeutic in the sample. In another exemplary embodiment, the enzyme's color producing substrate such as a modified N,N-dimethylaniline is immobilized to the membrane strip and 3-methyl-2-benzothiazolinone hydrazone is passively applied to the membrane, thus alleviating the need for a separate reagent to visualize the color producing reaction.

15 ***VII. Kits***

[0174] Another aspect of the present invention relates to kits useful for conveniently determining the presence or the concentration of active anti-HIV therapeutic in a sample. The invention also encompasses kits useful for conveniently determining the presence or the concentration of a PI or NRTI or EI, both active and inactive, in a sample. The kits of the
20 present invention can comprise a receptor specific for a met-sensitive moiety of an anti-HIV therapeutic or a PI or a NRTI or an EI. In an exemplary embodiment, the receptor is an antibody. In another exemplary embodiment, the receptor comprises the antigen-binding domain or antigen-binding residues that specifically bind to the met-sensitive moiety of an anti-HIV therapeutic or a PI Derivative or NRTI Derivative or EI Derivative. The kits can
25 optionally further comprise calibration and control standards useful in performing the assay; and instructions on the use of the kit. The kits can also optionally comprise a hapten-reactive partner conjugate. To enhance kit versatility, the kit components can be in a liquid reagent form, a lyophilized form, or attached to a solid support. The reagents may each be in separate containers, or various reagents can be combined in one or more containers depending on
30 cross-reactivity and stability of the reagents.

[0175] Any sample that is reasonably suspected of containing the analyte, *i.e.*, a met-sensitive moiety of a PI or NRTI or EI, or PI or NRTI or EI, can be analyzed by the kits of the present invention. The sample is typically an aqueous solution such as a body fluid from

a host, for example, urine, whole blood, plasma, serum, saliva, semen, stool, sputum, cerebral spinal fluid, tears, mucus, breast milk or the like. In an exemplary embodiment, the sample is plasma or serum. The sample can be pretreated if desired and can be prepared in any convenient medium that does not interfere with the assay. For example, the sample can be provided in a buffered synthetic matrix.


[0176] The sample, suspected of containing anti-HIV therapeutic, and a calibration material, containing a known concentration of the anti-HIV therapeutic, are assayed under similar conditions. Anti-HIV therapeutic concentration is then calculated by comparing the results obtained for the unknown specimen with results obtained for the standard. This is commonly done by constructing a calibration or dose response curve.

[0177] Various ancillary materials will frequently be employed in an assay in accordance with the present invention. In an exemplary embodiment, buffers and/or stabilizers are present in the kit components. In another exemplary embodiment, the kits comprise indicator solutions or indicator "dipsticks", blotters, culture media, cuvettes, and the like. In yet another exemplary embodiment, the kits comprise indicator cartridges (where a kit component is bound to a solid support) for use in an automated detector. In still another exemplary embodiment, additional proteins, such as albumin, or surfactants, particularly non-ionic surfactants, may be included. In another exemplary embodiment, the kits comprise an instruction manual that teaches a method of the invention and/or describes the use of the components of the kit.


EXAMPLES

[0178] The following examples are offered by way of illustration and not by way of limitation. Chemicals were purchased from Aldrich Chemical Co. (Milwaukee, WI), and used as received. Amino acids derivatives and resins were purchased from AnaSpect (San Jose, CA) or Advanced Chem Tech (ACT) (Louisville, KY). Silica gel plates were obtained from Analtech (Newark, DE). NMR spectra were recorded on a 300 MHz Bruker instrument. Chemical shifts are in ppm downfield from TMS and were recorded in the solvents listed. Splitting patterns are designated as follows: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad. The chemical synthesis and characterization of compounds carried out by Kimia Corp. (Santa Clara, CA).


EXAMPLE 1

*Preparation of a hapten comprising Met-Sensitive Moiety (H3)**1.1 Preparation of **11***

- 5 **[0179]** To a stirred solution of ketone **10** (900 mg, 5 mmol) in THF (10 mL) was added the sarcosine Cbz (1.55 g, 7 mmol) under an argon atmosphere. To the solution was added sodium borohydride (360 mg, 10 mmol) portion wise over 3 h at rt. To the reaction was then added HCl (1%) dropwise until hydrogen gas no longer evolved. DCM (20 mL) and brine (20 mL) were added to the mixture. The organic phase was separated and washed with brine (3X10 mL) and dried (Mg_2SO_4). The solvent was then removed and the residue was purified on a silica gel column (DCM:ethyl acetate; 80:20) to give the pure product as a white solid (965 mg, 50%).

*1.2 Preparation of **11***

- 15 **[0180]** To a stirred solution of derivative **11** (772 mg, 2 mmol) in ethanol (5 mL) was added Pd/C (10%). The mixture was hydrogenated at atmospheric pressure over night. The reaction mixture was filtered through a pad of celite and the filtrate was evaporated to dryness to give crude **12** as a thick oil that was used for the next step without further purification.


*1.3 Preparation of **12***

[0181] To a stirred solution of **12** (333 mg, 1.5 mmol) in pyridine (2 mL) and DMSO (1 mL) at -25°C was added a solution of the sulfonyl chloride (392 mg, 1.6 mL) in DCM (1 mL). The reaction was stirred for 3 h and then allowed to warm to rt. Brine (10 mL) and DCM (20 mL) were added. The organic layer was separated and washed with brine (2x15 mL) and dried (Na_2SO_4). The solvent was then removed under reduced pressure and the residue was purified on silica gel column (DCM:MeOH, 90:10) to give product **13** as a pale yellow solid (323 mg, 50%).

EXAMPLE 2


Preparation of a hapten comprising Met-Sensitive Moiety (H4)

2.1 Preparation of **15**



[0182] **14** was prepared as discussed in Turner *et al.*, *J.Med.Chem.*, **41**, 3467 (1998). To a stirred solution of **14** (520 mg, 2 mmol) in THF (5 mL) was added NaH (50% in oil, 100 mg, 2 mmol) at ice bath temp. After the hydrogen gas stopped evolving, a solution of the acrylate was formed (384 mg, 3 mmol). The reaction was stirred overnight and then DCM (20 mL) and brine (20 mL) were added. The organic phase was separated and washed with brine (3X20 mL) and dried (Mg_2SO_4). The solvent was then removed under reduced pressure to give crude **15** as a thick oil. The oil was further purified on a PTLC (silica gel, Hexane: ethyl acetate ; 40:60) to give pure **15** (194 mg, 50%) as a white solid.

2.2 Preparation of **16**




[0183] To a stirred solution of compound **15** (195 mg, 0.5 mmol) in DCM (10 mL) was added TFA (1 mL) at 0 °C. The reaction was stirred for 10 min. and then evaporated to dryness. The residue was then purified on a silica gel column (DCM:MeOH, 90:10) to give pure **16** (120 mg, 72%) as a white solid.

5

EXAMPLE 3

Preparation of a hapten comprising Met-Sensitive Moiety (H5)


3.1 Preparation of **2**



[0184] To a stirred solution of the m-amino phenyl acetate **1** (1.65 g, 10 mmol) in THF (20 mL) and DIEA (2 mL) at ice bath temperature was added a solution the sulfonyl chloride (2.69 g, 1.1 mmol) in DCM (20 mL) dropwise over a period of 1 h. The reaction was then allowed to reach rt and then brine (30 mL) and DCM (40 mL) were added. The organic phase was separated and washed with water (3X, 40 mL) and dried (Mg₂SO₄). The solvent was evaporated under reduced pressure. The residue was then purified on silica gel column (MeOH:DCM, 5:95) **2** as a pale yellow solid (3.1 g, 82%).

15


3.2 Preparation of **3**




[0185] To a stirred solution of compound **2** (1.87 g, 5 mmol) in MeOH (20 mL) and water (5 mL) was added sodium hydroxide solution (5N) to keep the pH at 11. The reaction was stirred for 4 h at rt. The pH was then adjusted to 3 by addition of a solution of HCl (5N). The solvent was then removed under the reduced pressure and the residue was extracted with DCM (3x20 mL). The combined organic layer was evaporated to dryness to give compound **3** (1.3 g, 82%) as a white foam that was pure.

20


EXAMPLE 4

*Preparation of a hapten comprising Met-Sensitive Moiety (H6)*4.1 Preparation of **6**

- 5 **[0186]** To a stirred solution of the phosphonate **5** (1.8 g, 10 mL) in THF (100 mL) at -75°C added n-butyl lithium solution (in hexane, 1N, 10.5 mL) dropwise over 30 min. The mixture was stirred at this temperature for one hour after complete addition of n-butyl lithium. To the reaction was then added a solution of nitro ketone **4** (716 mg, 4 mmol) in THF (20 mL). The reaction was kept at -75°C for 30 min and then was allowed to reach to
- 10 rt. Brine (100 mL) and DCM (100 mL) were added and the organic layer was separated and dried (Mg_2SO_4). The solvent was removed under reduced pressure and the residue was purified on a silica gel column (hexane: ethylacetate, 50:500) to give pure **6** as a yellow solid (705 mg, 75%).




- 15 **[0187]** A stirred solution of **6** (470 mg, 2 mmol) in MeOH (10 mL) was added was hydrogenated (Pd/C (10%, 100 mg)) at atmospheric pressure overnight. The reaction was filter through a pad of Celite and then was evaporated to dryness to give compound **7** (414 mg, 100%) as a white solid that was used for the next step without further purification.



- 20 **[0188]** To a stirred solution of compound **7** (207 mg, 1 mmol) in DCM (10 mL) and DIEA (1 mL) at 0°C was added, dropwise, a solution of the sulfonyl chloride (269 mg, 1.1 mmol) in DCM (5 mL). The reaction was then allowed to warm to rt and brine (10 mL) was added.

The DCM layer was separated and washed with water (3X 10 mL) and dried (Mg_2SO_4). The solvent was then removed under reduced pressure and the residue was purified on a silica gel column (MeOH: DCM, 5:95) to give the product **8** (390 mg, 93%) as a pale yellow foam.




- 5 **[0189]** To a stirred solution of **8** (390 mg, 0.93 mmol) in MeOH (5 mL) and water (1 mL) was added sodium hydroxide solution (5N) to keep the pH at 11. The reaction was stirred for 4 h or until TLS (silica gel, MeOH: DCM, 10:90) showed no starting material was left. The pH was adjusted to 3 by addition of HCl (4N). The solvent was evaporated under the reduced pressure and the residue was extracted with DCM (3x15 mL). The solvent was removed
- 10 under reduced pressure to give acid **9** (361 mg) as a yellow solid that was used for the next step without further purification.


EXAMPLE 5

Preparation of a hapten comprising Met-Sensitive Moiety (H7)

*5.1 Preparation of **10***




- 15 **[0190]** To a stir solution of acid **9** (180 mg, 0.5 mmol) in DCM (2 mL) was added EDCI at rt. The mixture was stirred for 3 h. A solution of the mono t-BOC (200 mg) in DCM (3 mL) was then added and the reaction was stirred overnight. The reaction mixture was then filtered and the solvent was removed under reduced pressure to give the crude **10**. The residue was
- 20 purified on a silica gel column (DCM: MeOH, 5:95) to give pure **10** (226 mg, 90%) as a white foam.


5.2 Preparation of **11**

[0191] To a stirred solution of **10** (226 mg, 0.45 mmol) in DCM (4 mL) was added TFA (1 mL) and the mixture was kept at rt for 30 min. The solvent was removed under the reduced pressure and the residue was co-evaporated with CHCl_3 3x. To the residue was added DCM (4 mL), bromoacetyl NHS and DIEA (0.5 mL). The reaction was stirred overnight. The reaction was mixed with water (10 mL) and DCM (20 mL). The organic layer was separated and washed with water (3x10 mL) and dried (MgSO_4). The solvent was then removed and the residue was purified on a silica gel column (MeOH:DCM, 5:95) to give the truncated tipranavir **11** (188 mg, 80%) as a pale yellow foam.

EXAMPLE 6


Preparation of a hapten comprising Met-Sensitive Moiety (**H8**)6.1 Preparation of **2**

[0192] To a solution of NaH (60% in oil) in THF (40 mL) was added trimethylphosphonoacetate (2.1 mL) in dry THF at 0 °C. After the end of gas evolution, (about 15 min) **1** (2.0 g in 10 mL THF) was added drop wise. After 1hr, thin layer chromatography showed no starting material. THF was evaporated. Water was added and the aqueous layer was extracted with EtOAc (2x50mL). Organic layer was washed with brine and dried (MgSO_4). After removal of solvent, 3.1 g crude desired product **2** was obtained which was used in the next step without purification.


6.2 Preparation of **3**

[0193] To a solution of **2** (3.1g, 13 mmol) in MeOH (25 mL) was added Pd/C 10 % (500 mg) catalyst and the mixture was hydrogenated (1 atm) until no starting material was left (24 h). The reaction mixture was filtered over celite and catalyst was washed with EtOAc (50 mL). The combined filtrate was concentrated and purified by flash chromatography. (0 to 30% EtOAc /Hex gradient) to give 1.94 mg clean desired product (71% yield for two steps).

[0194] Mass m/e (M+1); 208. ¹H NMR (CDCl₃); 0.80 (3H, t, j=7.3 Hz), 1.65 (2H, m), 2.57 (2H, m), 2.90 (1H, m), 3.05-3.60 (2H, NH₂), 3.60 (3H, s), 6.50 (1H, m), 6.56 (2H, m), 7.06 (1H, m).

6.3 Preparation of **4**


[0195] To a solution of **3** (200 mg, 0.96 mmol) in DCM (2 mL) and pyridine (1 mL) was added 5-trifluoromethyl-2-pyridine sulfonyl chloride in DCM (2 mL) and the reaction mixture was allowed to stir at room temperature. After 15 min no starting material was left. EtOAc (50 mL) and water (50 mL) were added. Organic layer was separated and washed with water, HCl 1N (25 mL) and brine. After drying (MgSO₄), solvent was removed and the crude was purified by flash chromatography. To give 360 mg (90% yield) of desired product **4**. NMR and LC/MS confirm the structure of **4**.

6.4 Preparation of **5**

[0196] 300 mg of intermediate **4** was treated with KOH 2.5N (1 mL) in MeOH (4mL). After overnight stirring more KOH 2.5 N (1 mL) was added. Four hrs after second addition, the reaction was complete. The reaction mixture was acidified (pH =3) and extracted with DCM. The desired material was obtained as a white solid (265 mg, 92 % yield) very clean judging by NMR, tlc, and LC/MS (purity; 96.5 %).

[0197] Mass M/e (m+1); 403. ¹H NMR (*dms*o d₆); 0.48 (3H, t, j= 6.9 Hz), 1.33 (1H, m), 1.52 (1H, m), 2.35 (1H, m), 2.51 (1H, m), 2.71 (1H, m), 6.86 (2H, m), 6.93 (1H, m), 7.12 (1H, m), 8.08 (1H, d, j=8.1 Hz), 8.43(1H, m), 9.13 (1H, s), 10.67 (1H, bs), 11.95 (1H, bs).


EXAMPLE 7

Preparation of a hapten comprising Met-Sensitive Moiety (**H9**)7.1 Preparation of **3**

[0198] To a stirred solution of tipanavir **1** (301 mg, 0.5 mmol) in DCM (5 mL) and anhydrous pyridine (0.5 mL) was added Cbz-carboxymethyl isocyanate **2** (249 mg, 1mmol, prepared from Cbz-alanine and phosgene). The mixture was stirred overnight under an argon atmosphere. The mixture was then diluted with DCM (20 mL) and aqueous HCl (10 mL,

5%). The organic layer was separated and washed with water (10 mL) and dried (Na_2SO_4). The organic layer was evaporated and the residue was purified on a column (silica gel, ethyl acetate, DCM: 10:90) to give the tipanavir derivative **3** as a foam (335 mg, 80%).

7.2 Preparation of **4**




[0199] To a stirred solution of derivative **3** (330 mg, 0.39 mmol) in MeOH (10 mL) was added Pd/C (20 mg, 10%) under an atmospheric pressure of hydrogen 4 h. The reaction mixture was then filtered through a pad of Celite. The filtrate was evaporated to dryness under vacuum. The residue was purified on a column (silica gel, DCM: MeOH, 95:5) to give **4** (273 mg, 0.39 mmol, 100%) as a white solid.

EXAMPLE 8

Preparation of a hapten comprising Met-Sensitive Moiety (H10)


8.1 Preparation of **6**



[0200] **5** was prepared as disclosed in Turner *et al.*, *J. Med. Chem.*, **41**, 3467 (1998). A sulfonyl chloride solution (222 mg, 1.1 mmol) in DCM (2 mL) was produced according to Fors, K *et al.*, *J. Organic Chemistry*, **63**, 7348 (1998). Intermediate **5** (393 mg, 1 mmol) in pyridine (2 mL), DMSO (1 mL) and DCM (1 mL) was added to the sulfonyl chloride solution at -25°C and under an atmosphere of argon. The reaction was stirred for 3 h and allowed to come to rt. The mixture was added to DCM (20 mL) and washed with brine (3X 10 mL), HCl (5%, 10 mL) and water (3X10 mL) and dried (Na_2SO_4). The solvent was removed under


reduced pressure to give a yellow oil. The oil was purified on a column (silica gel, DCM:ethyl acetate, 80:20) to give compound **6** as a pale yellow foam (475 mg, 85%).

8.2 Preparation of **7**




- 5 **[0201]** To a stirred solution of **6** (279, 0.5 mmol) in anhydrous ethanol (5 mL) was added Pd/C (20 mg, 10%) and Raney Nickel (30 mg). The mixture was hydrogenated at 50 PSI hydrogen pressure overnight. The mixture was then filtered through a pad of Celite. The filtrate was evaporated to dryness under reduced pressure. The residue was further purified on a silica gel column (DCM: MeOH, 90:10) to give compound **7** (279 mg, 100%) as a white solid.
- 10

8.3 Preparation of **8**




- [0202]** To a stirred solution of **7** (225 mg, 0.4 mmol) in DMF (3 mL) was added bromoacetyl – NHS ester. The reaction was subsequently stirred overnight at rt. The reaction mixture was evaporated to dryness under vacuum. The residue was then purified via PTLC (silica gel, DCM: MeOH; 98:2) to give the bromo acetyl derivative **8** as a pale yellow solid (219 mg, 80%).
- 15

EXAMPLE 9


*Preparation of a hapten comprising Met-Sensitive Moiety (H11)**9.1 Preparation of **2***

- 5 **[0203]** To a stirred solution of **1** (225 mg, 0.4 mmol) in DMF (3 mL) was added succinic anhydride (60 mg, 0.6 mmol) and the reaction was stirred overnight at rt. The reaction mixture was evaporated to dryness under vacuum. The residue was then purified via PTLC (silica gel, DCM: MeOH, 98:10) to give the bromo acetyl **2** as a white solid (199 mg, 75%).

EXAMPLE 10

*10 Preparation of a hapten comprising Met-Sensitive Moiety (H12)**10.1 Preparation of **2***

- 15 **[0204]** To a solution of **1** (300 mg, 0.5 mmol) in dry DMF (3 mL) was added DIEA (84 μ L, 0.5 mmol) followed by t-butyl bromoacetate (71 μ L, 0.5 mmol). The mixture was allowed to stir over night at room temperature. EtOAc and water were added (25 mL each) and organic layer was separated and washed with HCl, 1N (5 mL), water, and brine. It was then dried (MgSO_4) and concentrated to give 350 mg crude, which was purified to 190 mg (54% yield) desired product.
- 20 **[0205]** Mass, m/e (M+1); 717; ^1H NMR (CDCl_3); 0.82 (3H, t, $j=7.5$ Hz), 0.91 (3H, t, $j=7.2$ Hz), 1.49 (9H, s), 1.27-2.20 (10H, mass), 2.42(2H, q, $j=9\text{Hz}$), 2.62(2H, m), 4.01 (1H, t, $j=9\text{Hz}$), 4.25-4.38(2H, m), 6.80-7.27(8H, mass), 7.96-8.04 (2H, m), 8.92(1H, m).


10.2 Preparation of **3**

[0206] To intermediate **2** (200 mg, 0.28 mmol) was added TFA (3 mL) and allowed to stir at room temperature for 2 hrs. Tlc showed no starting material. TFA was evaporated, DCM was added (2x5 mL) and evaporated. The solid material was left under vacuum to dryness. 170 mg (92% yield) desired product **3** was obtained with >97% purity.

[0207] Mass m/e (M+1); 662. ¹H NMR (CDCl₃); 0.84 (3H, t, j=7.2 Hz), 0.91 (3H, j=7.5 Hz), 1.27-1.38 (4H, m), 1.70-2.20 (6H, mass), 2.40-2.80 (4H, m), 4.05 (1H, t, j=8.1 Hz), 4.44 (2H, dd, j=16.1 and 5.1 Hz), 6.92-7.41 (9H, mass), 8.02 (2H, m), 8.94 (1H, m).

10

EXAMPLE 11

Preparation of a hapten comprising Met-Sensitive Moiety (**K1**)11.1 Preparation of 3-hydroxyhexahydrofuro(2,3-b) furan derivative **2**

[0208] A solution of Fmoc phenyl glycine (3.3 g, 8.64 mmol) and DIEA (3.0 mL, 17.28 mmol) in dried dichloromethane (10 mL) was added to the chlorotrityl resin (1.08 mmol/g, 2 g). The suspension was shaken overnight at rt. The resin was then washed with DMF (3x10 mL), DCM (3x10 mL) and MeOH (3x10 mL) respectively and dried under vacuum to give 3.1 g of the resin. The resin gave a negative test for ninhydrin. To the resin was added a solution of 20% piperidine in DMF (15 mL) and the mixture was shaken for 30 min on a shaker. The resin was then filtered and washed with DMF (3x20 mL), DCM (3x20 mL) and MeOH (2x20 mL) respectively. The resin gave a positive test for ninhydrin. The chloroformate **1** (prepared by reaction of the alcohol with excess phosgene, as shown by Ghosh, *et al.*, *J. Org. Chem.*, **69**, 7822 (2004)) was then added slowly to the suspension of the

15


20

resin in DCM (5 mL) and DIEA (1.9 mL, 11.9 mmol) at rt and the suspension was shaken for 2 h. After this time, a sample of the resin gave a negative test for ninhydrin. The resin was filtered and washed with a solution of 10% DIEA in DCM (10 mL), DCM (3x15 mL) and MeOH (20 mL) respectively. The resin was then dried under vacuum to dryness. To the resin was then added a mixture of TFA, AcOH and DCM (10 mL, 1:1:8) and the resulting mixture was shaken for 30 min. The resin was filtered and washed with DCM (10 mL). The combined filtrates were evaporated to dryness under vacuum to give 617 mg of the crude product as a viscous oil. The crude product was then dissolved in EtOAc (30 mL) and treated with a saturated solution of bicarbonate (3 mL). The pH of the aqueous layer was 12. Water (10 mL) was then added and the aqueous layer was separated. The aqueous layer was extracted with EtOAc (2x20 mL). The aqueous layer was then acidified by slow addition of HCl (1N) to pH 4. The acidic solution was then extracted with EtOAc (3x30 mL). The organic layer was then washed with brine (5 mL) and dried (MgSO₄). The solvent was then removed under vacuum to give the pure product **2** (321 mg, 10%) as a white solid.


EXAMPLE 12

Preparation of a hapten comprising Met-Sensitive Moiety (K2)

12.1 Preparation of **12**




[0209] An ice-cold solution of t-Boc epoxide (2.6 g, 10 mmol) in ammonia and MeOH (50 mL) was stirred for 4 h. The solvent was then removed under reduced pressure. The crude residue was dissolved in THF (50 mL), DIEA (1.89 mL, 11 mmol) and benzylchloroformate (1.87 g, 11 mmol) and stirred overnight. The reaction was quenched with water (50 mL) and extracted with ethyl acetate (2x100 mL). The combined organic layers were washed with saturated Na₂CO₃ (100 mL), brine (100 mL), dried (Na₂SO₄) and evaporated to dryness. The crude residue was purified on a column (silica gel, ethyl acetate:hexane, 60:40) to give cbz protected product (2.48 g, 0.60%) as a foam. The product was dissolved in THF/HCl (4N, 100 mL) and stirred for 2 h. The solvent was removed to give pure **12** as a white solid (1.88 g, 100 %).

12.2 Preparation of **15**


[0210] To a stirred solution of amine **12** (942 mg, 3 mmol) and DIEA (1 mL) in THF (10 mL) was added chloroformate **1** (595 mg, 3.1 mol) at ice bath temperature over a period of 1 h. The reaction was then allowed to warm to rt overnight. To the reaction mixture was then added water (50 mL) and the mixture was extracted with DCM (3x30 mL). The combined organic layers were washed with saturated Na₂CO₃ (10 mL), brine (30 mL) and dried (Mg₂SO₄). The solvent was removed under reduced pressure and the residue was purified on a column (silica gel, DCM:MeOH, 95:5) to give (1.15 g, 75%) of the cbz protected product that was hydrogenated as described before to give **15** (672 mg, 2 mmol, 66%) as a pale yellow solid.

EXAMPLE 13

Preparation of a hapten comprising Met-Sensitive Moiety (**K3**)13.1 Preparation of **16**, a bromoacetyl derivative of **15** (fragment)


[0211] To a stirred solution of the amine **15** (168 mg, 0.5 mmol) in DMF (3 mL) was added bromo acetyl NHS ester (130 mg, 0.6 mmol). The mixture stirred overnight and then diluted with water (10 mL). The mixture was then extracted with DCM (3x30 mL). The combined DCM layers were washed with brine (30 mL), dried (Mg₂SO₄) and evaporated to dryness under vacuum. The crude was then purified on a column (silica gel, DCM:MeOH, 95:5) to give the bromoacetyl derivative **16** (110 mg, 48%) as a white foam.

EXAMPLE 14

*Preparation of a hapten comprising Met-Sensitive Moiety (K4)**14.1 Preparation of methyl carboxyl 17 (fragment)*

- 5 **[0212]** To a stirred solution of the acid 2 (321 mg, 1 mmol) in DMF (2 mL) was added DCC (260 mg, 1.2 mmol) and NHS (120 mg, 1.4 mmol). The mixture was stirred for 6 h and then glycine (150 mg, 2 mmol) and DIEA (0.4 mL, 2 mmol) were added at rt and the reaction was stirred overnight. The solvent was then evaporated to dryness under vacuum. To the residue was added water (10 mL) and extracted with ethyl acetate (2x25 mL). The combined
- 10 organic layer was then washed with HCl (1N, 4 mL), and saturated sodium bicarbonate (3 mL) and dried (Na₂SO₄). The ethyl acetate was removed under reduced pressure to give the crude product. The crude product was purified on a silica gel column (MeOH:DCM:AcOH, 10:90:0.1) to give pure product 17 (170 mg, 45%) as a white foam.

EXAMPLE 15

15 *Preparation of a hapten comprising Met-Sensitive Moiety (K5)**15.1 Preparation of 19*


- [0213]** To a stirred solution of 18 (136 mg, 0.25 mmol) in THF (1 mL) was added succinic anhydride (50 mg, 0.5 mmol). The reaction was then stirred at rt overnight. The mixture was then added to brine (5 mL) and DCM (10 mL). The organic layer was separated and washed with brine (5 mL). The organic phase was dried (Na₂SO₄) and evaporated to dryness. The
- 20

crude mixture was then purified on a silica gel column (MeOH:DCM, 5:95) to give acid **19** (54 mg, 33%) as a white foam.

EXAMPLE 16

Preparation of a hapten comprising Met-Sensitive Moiety (K6)

16.1 Preparation of **20**




[0214] To a stirred solution of **18** (272 mg, 0.5 mmol) in THF (1 mL) at -10°C and under an argon atmosphere was added a solution of bromoacetyl chloride (86 mg, 0.55 mmol) in THF (0.5 mL) over one hr. After the addition was completed, the reaction was stirred for 1 h at -10°C and then allowed to warm to rt. The reaction mixture was added to brine (10 mL) and DCM (10 mL). The organic layer was separated and extracted with brine (5 mL), water (5 mL) and dried (Na_2SO_4). The organic phase was then filtered and evaporated to dryness to give the crude **20**. The crude was purified on a silica gel column (ethyl acetate: hexane, 80:20) to give the desired product **20** (100 mg, 30%) as a pale yellow foam.


EXAMPLE 17

Preparation of a hapten comprising Met-Sensitive Moiety (L1)

17.1 Preparation of **3**




[0215] A suspension of tenofovir, **1**, (130 mg, extracted from the medication using DCM) and succinic anhydride (100 mg, 1 mmol) in xylene (3 mL) was heated in a oil bath at 100°C overnight. The solvent was then removed under reduced pressure and the residue was purified on a column (silica gel, DCM: MeOH, 97:3) to give the pure product, **2** (120 mg).

17.2 Preparation of **3**

[0216] A solution of the ester **2** (120 mg) was dissolved in MeOH (10 mL) and H₂O (2 mL). The pH was adjusted to 10 by addition of sodium hydroxide (5N). The mixture was kept for 30 min. at this pH. TLC showed no starting material; at this point, the pH was adjusted to 3 by addition of HCl (1N). The solvent was removed under reduced pressure and the residue was dissolved in anhydrous MeOH and filtered. The solvent was removed under reduced pressure to give the acid **3** as an oil.


EXAMPLE 18

10 Preparation of a hapten comprising Met-Sensitive Moiety (M1)

18.1 Preparation of **2**


[0217] A mixture of lamivudine **1** (650 mg, 2 mmol) and bromoacetyl NHS ester (497 mg, 2.1 mmol) in DMF (3 mL) was stirred overnight. The reaction mixture was purified on a HPLC (C18, 5-95% AcCN:H₂O: 0.1 TFA) to give the pure product **2** (180 mg) as a white solid.

EXAMPLE 19

*Preparation of a hapten comprising Met-Sensitive Moiety (M2)**19.1 Preparation of 3*

- 5 [0218] A mixture of lamivudine 1 (650 mg, 2 mmol) and succinic anhydride (231 mg, 2.1 mmol) in dried DMF was stirred overnight at rt. The reaction mixture was directly purified on a HPLC (C18, AcCN: H₂O: TFA, 5-95: 0.1) to give 200 mg of the product 3 as a white solid.

EXAMPLE 20

10 *Preparation of a hapten comprising Met-Sensitive Moiety (N1)**20.1 Preparation of 3*

- [0219] To a stirred suspension of 2 (1.65 g, 10 mmol) in THF (20 mL) at 0 °C was added imidazole (1.36 g, 20 mmol) under an atmosphere of N₂. To the suspension was added dropwise solution of TMSCl (2.5 mL, neat). The reaction was stirred overnight to give a pale yellow solution of the TMS ester of 2 as a pale yellow solution that was used for the next step without further purification.
- 15


- [0220] To a stirred solution of 1 (820 mg, 5 mmol) and DIEA (1.04 mL, 6 mmol) in DMF (10 mL) was added EDCI (1.159 g, 6 mmol) at RT. The reaction was stirred overnight. To the reaction was then added the above TMS ester in THF via a syringe (12 mL). After the addition was completed the reaction stirred for 4 hrs at RT. Brine (30 mL) was added and the reaction was acidified to pH 3 by addition of HCl (10 N). The acidic mixture was extracted with DCM (3X100 mL). The combined DCM mixture was washed with brine (3X40 mL)
- 20

and water (2x30 mL) and brine (40 mL) and dried (MgSO_4). The DCM phase was dried (MgSO_4), filtered and evaporated to dryness under vacuum to give a thick yellow oil. The oil was then purified on a silica gel column (DCM:MeOH:AcOH, 80:20:0.1) to give pure product **3** (933 mg, 60%) as a white solid.

EXAMPLE 21

Preparation of a hapten comprising Met-Sensitive Moiety (N2)


21.1 Preparation of **4**




[0221] To a saturated solution of MeOH (200 mL) in HCl gas at 0 °C was added acid **3** (3.11 g, 10 mmol). The mixture was stirred overnight at RT. The solvent was removed under the reduced pressure. The residue was dissolved in ether (100 mL) and washed with saturated K₂CO₃ (3X30 mL) and water (2X20 mL) and dried (MgSO₄). The ether phase was then filtered and evaporated to dryness to give the corresponding ester (3.11 g, 95%) that was used for the next step without further purification.

[0222] To a stirred solution of the above ester (1.62 g, 5 mmol) in dried THF (20 mL) at 0 °C was added portion was LiAlH₄ (114 mg, 3 mmol). After the addition was completed, the ice bath was removed and the reaction mixture was stirred at RT for four hrs. To the reaction was then added H₂O (114 µL), 15% NaOH (114 µL) and H₂O (342 µL) and the stirring was continued for further 30 min. The reaction was then filtered and the filtrate was evaporated to dryness. The residue was dissolved in DCM and purified on a silica gel column (DCM: MeOH, 95:5) to give the pure alcohol (1.189 g, 80%) as a thick oil.

[0223] To a stirred solution of the above alcohol (1.188 g, 4 mmol) in acetone (10 mL) at ice bath temperature was added dropwise a solution of Jones reagent. The reaction was then stirred for 1 hr at 4 °C and the partitioned between H₂O:DCM (30 mL, 1:2). The aqueous layer was separated and extracted with DCM (20 mL). The combined organic layer was washed with saturated solution of NaHCO₃ (10 mL), dried (Na₂SO₄) and concentrated under reduced pressure to give the crude aldehyde **4**. The aldehyde was purified on a silica gel column (DCM: AcOH, 80:20) to give the pure aldehyde **4** (885 mg, 75%).

21.2 Preparation of 5


[0224] To a stirred solution of aldehyde 4 (886mg, 3 mmol) in MeOH (10 mL) was added ammonium acetate (1.3 g) and the mixture stirred for 30 min. Sodium cyanoborohydride was then added portion wise (4X 100 mg) over a period of 2 hrs. To the mixture was then added water (2 mL) and the reaction was stirred for 20 more min. The solvent was then removed under reduced pressure. The residue was dissolved in DCM and filtered. The filtrate was purified on a silica gel column (DCM: MeOH, 90:10) to give the pure 5 (590 mg, 65%) as a thick pale yellow oil.

21.3 Preparation of 6

[0225] To a stirred solution of 5 (295 mg, 1 mmol) in DMF (3 mL) was added bromoacetyl – NHS ester and the reaction was stirred overnight at RT. The reaction mixture was evaporated to dryness under vacuum. The residue was purified on a PTLC (silica gel, DCM: MeOH; 98:2) to give the bromo acetyl 6 as a pale yellow solid (250 mg, 59%).

EXAMPLE 22

Preparation of a hapten comprising Met-Sensitive Moiety (N3)

22.1 Preparation of 7

[0226] A solution of the amine 5 (298 mg, 1 mmol), bromoacetate (184 mg, 1.2 mmol) and DIEA (226 μ L, 1.5 mmol) in DMF (2 mL) was stirred overnight at 70 °C. The mixture

was then diluted with water (15 mL) and DCM (15 mL) and the pH was adjusted to 3 by slow addition of con. HCl. The DCM layer was separated and washed with water (2X10 mL) or until the water layer was neutral. The DCM layer was dried (Na₂SO₄) and evaporated to dryness. The residue was then purified on a silica gel column (DCM: MeOH, 98:2) to give the pure methyl ester of **7** (310 mg, 84%).

[0227] To a stirred solution of the above methyl ester (300 mg, 0.8 mmol) in MeOH (8 mL) was added DI water (2 mL) and NaOH (5N) to keep the pH at 12 (the pH was checked every ½ hr) for 3 hrs. After 3hrs the TLC showed no starting material (silica gel, DCM: MeOH, 98:2). The pH was then adjusted to 6 by slow addition of HCl (1N). The solvent was then removed under the reduced pressure to a foam. The foam was dissolved in anhydrous MeOH (10 mL) and filtered through a plug of cotton. The solvent was removed under vacuum to give the pure acid **7** as a white foam (230 mg, 81%).

EXAMPLE 23

Immunogen Formation Involving Carboxylic Acids

[0228] **(H3)** is used in this Example. However, this conjugation technique is generally applicable to all met-sensitive moieties and NNRTI derivatives which are conjugated through a carboxylic acid moiety. The hapten is activated upon conversion of the carboxylic acid moiety to N-hydroxysuccinimide (NHS) ester. This Example specifically applies to compounds **(H3)**, **(H4)**, **(H5)**, **(H6)**, **(H8)**, **(H9)**, **(H11)**, **(H12)**, **(K1)**, **(K4)**, **(K5)**, **(L1)**, **(M2)**, **(N1)**, and **(N3)**.

A. Activation of (H3)

[0229] To a stirred solution of **(H3)** (10.7 mg, 30.8 mmol) in dried DMF (0.5 mL) is added 1-ethyl-3-(3-dimethylamino propyl)carbodiimide (EDAC) (5.7 mg, 29.7 mmol) and N-hydroxysuccinimide (NHS) (4.9 mg, 42.6 mmol) at ice bath temperatures. The mixture is stirred overnight. Ester formation is monitored by TLC analysis.

B. Conjugation of (H3) to KLH

[0230] Two vials of lyophilized KLH (Pierce, 27 mg per vial) are reconstituted with 2 mL of deionized water each and pooled. The mixture is allowed to stand overnight at 4 °C. A buffer exchange is done by dialyzing overnight the KLH solution against 2 L of sodium bicarbonate buffer (0.1 M, pH 8.9). The final volume of the KLH preparation is 3.75 mL at a concentration of 14.4 mg/mL. A 1.2 mL aliquot of the KLH preparation (17.28 mg) is

transferred into a reaction vial. The solution of Example 40 A (320 μ L) is then added slowly (10-20 μ L per addition) to the solution of KLH over a period of 2 h at ice bath temperatures. After the addition is completed, the mixture is stirred in a 4 °C cold room overnight. This solution is then dialyzed against three changes (2.0 L each) of HEPES buffer (10 mM, pH 7.0, 1 mM). The final concentration of the KLH preparation is 4.5 mg/mL.

C. Conjugation of (H3) to Glucose-6-Phosphate Dehydrogenase

[0231] Lyophilized G6PDH (Worthington Biochem. Corp., 42.2 mg) is reconstituted with 3.5 mL deionized water to give a solution of 12.1 mg/mL. The mixture is allowed to stand overnight at 4 °C. The mixture is then dialyzed overnight at 4 °C against 2 L of sodium bicarbonate buffer (0.1 M, pH 8.9). After dialysis, 0.6 mL (7.2 mg) of enzyme solution is transferred to a reaction vial.

[0232] The activated product of Example 23 A was added in 5 to 10 μ L quantities to a solution of glucose-6-phosphate dehydrogenase (G6PDH, 0.1 M in sodium carbonate buffer) glucose-6-phosphate (G6P, 4.5 mg/mg G6PDH), and NADH (9 mg/mg G6PDH) in a pH 8.9 sodium carbonate buffer at ice bath temperature. After the addition of each portion of solution of Example 23 A a 2 μ L aliquot is taken and diluted 1:500 with enzyme buffer. A 3 μ L aliquot of this diluted conjugation mixture can be assayed for enzymatic activity similar to that described in Example 26 A below. The reaction is monitored and stopped at 59.3 % deactivation of enzyme activity. The mixture is desalted with a PD-10 pre-packed Sephadex G-25 (Pharmacia, Inc.) and pre-equilibrated with HEPES buffer (10 mM, pH 7.0, 1 mM EDTA). The reaction mixture is applied to the column and the protein fractions pooled. The pooled fractions are dialyzed against three (1.0 L each) changes of HEPES (10 mM, pH 7.0, 1 mM EDTA) to yield a solution of the conjugate.

D. Determination of the Number of Met-Sensitive Moieties on an Immunogenic Carrier

[0233] KLH conjugated product from Example 23 B buffer are dialyzed against bicarbonate buffer (0.1 M, pH 8.5). A series of known concentrations of glycine standards (Pierce) ranging from 2 to 20 μ g/mL are prepared in bicarbonate buffer (0.1 M, pH 8.5). 0.25 mL of the 0.01% (w/v) solution of 2,4,6-trinitrobenzene sulfonic acid (Pierce, TNBS) is added to 0.5 mL of each sample solution and mixed well. Reaction mixture is incubated at 37 °C for 2 h. After the mixture is cooled to rt, 0.25 mL of 10% sodium dodecyl sulfate (SDS) and 0.125 mL of 1 N HCl is added to each sample. The absorbance of the sample and standard solutions at 340 nm can be measured, and the quantitative determination of the

number of amines contained within a KLH sample can be accomplished through comparison to a glycine standard curve, according to the method of given in Bioconjugate Techniques, p.112-113, 1966, Academic Press, San Diego, California, incorporated herein by reference.

EXAMPLE 24

5 *Immunogen Formation Involving Halogens*

[0234] (H7) is used in this Example. However, this conjugation technique is generally applicable to all met-sensitive moieties and NNRTI derivatives which are conjugated through a bromine moiety. This Example specifically applies to compounds (H7), (H10), (K3), (K6) (M1) and (N2).

10 *A. Activation of KLH*

[0235] One vial of lyophilized KLH (Pierce, 27 mg) is reconstituted with 1 mL of deionized water. This KLH solution is dialyzed against phosphate buffer (0.1 M, 0.15 M NaCl, 1 mM EDTA, pH 8.0). The dialyzed KLH is transferred to a reaction vial. 2-Iminothiolane (2-IT) (Pierce, 4.0 mg, 29.1 μ mol) is dissolved in water to give a 2 mg/mL solution. The 2-IT solution is added to KLH with stirring. After 75 min, the mixture is
15 desalted with a PD-10 pre-packed Sephadex G-25 (Pharmacia, Inc.) and then pre-equilibrated with phosphate buffer (100 mM, pH 8, 1 mM EDTA) to remove excess 2-IT.

B. Procedure for Quantitating Sulphydryl Groups Using a Cysteine Standard

[0236] Cysteine standards ranging from 0 to 1.5 mM are prepared by dissolving cysteine
20 hydrochloride monohydrate in Reaction Buffer (0.1 M sodium phosphate, pH 8.0, containing 1 mM EDTA). A set of test tubes are prepared, each containing 50 μ L of Ellman's Reagent Solution (Pierce, dissolve 4 mg Ellman's Reagent in 1 mL of Reaction Buffer) and 2.5 mL of Reaction Buffer. 250 μ L of each standard or KLH is added to the separate test tubes. KLH samples are appropriately diluted so that the 250 μ L sample applied to the assay reaction has
25 a sulphydryl concentration in the working range of the standard curve. The reaction mixture is incubated at room temperature for 15 min. The absorbance is measured at 412 nm. The values obtained for the standards are plotted to generate a standard curve. KLH sample concentrations are determined from the curve.

C. Conjugation of Thiolated KLH to (H7): Formation of an Immunogen

30 [0237] Dithiothreitol (DTT, 5 mM, 2.3 mg) is added to thiolated KLH. The solution is allowed to mix overnight at 4 °C. (H7) (9.3 mg, 21.7 μ mol) is dissolved in 0.5 mL DMF.

After stirring for 1 h, the dissolved product is added in 5 to 10 μ L quantities to a solution of thiolated KLH from Example 24 A. The solution comprising **(H7)** is added until a slight precipitation was observed. The reaction is continued overnight at 4 °C. This solution is dialyzed against three changes (2.0 liter each) of HEPES buffer (10 mM, pH 7.0, 1 mM EDTA).

EXAMPLE 25

Immunogen Formation Involving Amines

[0238] This conjugation technique is generally applicable to all met-sensitive moieties and NNRTI derivatives which are conjugated through an amine moiety. This Example specifically applies to compound **(K2)**.

A. Activation of KLH: Succinylation

[0239] Lyophilized succinylated KLH (Sigma, 11 mg) is reconstituted with 2 mL deionized water. The KLH solution is dialyzed overnight two changes (2.0 L each) MES buffer (0.1 M MES, 0.9 M NaCl, 0.02% NaN₃, pH 4.7). After dialysis 6 mg of succinylated KLH is transferred to a reaction vial. **(K2)** (3.7 mg, 11.1 μ M) is dissolved in dry DMF and added to the reaction vial slowly. EDC (Pierce, 10 mg) is dissolved in 1 mL deionized water and immediately add 50 μ L of this solution to the KLH-**(K2)** solution. Additional EDC aliquots (10 μ L per addition) are added until slight precipitation occurred during the conjugation reaction. The reaction is allowed to proceed for approximately 2 h under constant mixing at room temperature. The reaction mixture is then dialyzed against three changes (2.0 L each) of HEPES buffer (0.05 M, pH 7.2, 1 mM EDTA).

EXAMPLE 26

Immunogen Formation Involving Sulfhydryls

[0240] This conjugation technique is generally applicable to all PIs and NNRTIs which are conjugated through a sulfhydryl moiety.

A. Conjugation of compound to bromoacetylated G6PDH

[0241] 50 μ L DMF of the compound is added to bromoacetic acid NHS (Sigma 3.06 mg, 12.97 μ M) and stirred. A 2.0 mL (10 mg/mL) G6PDH solution is prepared in 0.05 M Tris HCl buffer, pH 8.2. 45 mg disodium G6P and 90 mg NADH, is dissolved in the G6PDH solution. Bromoacetic acid NHS is added to G6PDH solution at 5 μ L increments. Enzyme activity is measured on the Cobas Mira analyzer after each addition. Bromoacetic acid NHS

is added until 63.6% enzyme deactivation was obtained. G6PDH conjugation solution is dialyzed with 3 x 4 liter portions of 0.01 M phosphate, pH 7.2.

(3.0 mg, 6.87 μ M) of the compound is dissolved in 125 μ L carbitol, plus 6.5 μ L 20 mM acetate buffer, pH 4.5. Carbitol and buffer are degassed before use. TCEP HCl is added (2.0 mg, 6.98 μ M) and mixed for 2 h.

[0242] To the G6PDH solution 5 μ L increments of the compound solution was added. The total addition took less than 1 hour. Conjugation is reacted overnight at 4 °C. The solution is transferred to a dialysis bag and dialyzed with 3 x 4 liter portions of 0.01 M phosphate, pH 7.2, at 4 C°.

EXAMPLE 27

Preparation of Monoclonal Antibodies reactive to Met-Sensitive Moiety (H12)

A. Hybridoma Production

[0243] Standard hybridoma procedures used have been described in detail (Kohler, G. *et al.*, *Nature* **256**: 495-497 (1976); Hurrell, Monoclonal Hybridoma Antibodies: Techniques and Applications, CRC Press, Boca Raton, FL (1982)). This hybridoma technique is generally applicable to produce monoclonal antibodies to the met-sensitive moieties and PI Derivatives, NRTI Derivatives and EI Derivatives of the invention.

[0244] 5 mice (Balb/c) were immunized with an immunogen comprising Met-Sensitive Moiety (**H12**) and KLH ("Immunogen (**H12**)/KLH") according to the schedule shown in Table 2.

Table 2. Immunization Schedule

Immunization	Immunogen	Amount	Adjuvant	Delivery
Initial	Immunogen (H12)/KLH	100 µg	FCA	ip
2 week	Immunogen (H12)/KLH	100 µg	FIA	ip
4 week	Immunogen (H12)/KLH	100 µg	FIA	ip
<u>8 week</u>				
Day - 3	Immunogen (H12)/KLH	100 µg	HBSS	sc
Day - 2	Immunogen (H12)/KLH	100 µg	HBSS	sc
Day - 1	Immunogen (H12)/KLH	100 µg	HBSS	sc

[0245] At the end of this immunization schedule, mice are sacrificed and the spleens removed and are ready for fusion to myeloma cells. The parental myeloma line used for all fusions is P3X63 Ag 8.653. Approximately $3\text{--}3.5 \times 10^7$ myeloma cells per spleen are spun down at 800 rpm for 8 min, then resuspended in 20 mL of DMEM. The excised spleens are cut into small pieces, gently crushed in a tissue homogenizer containing 7 mL DMEM, then added to the myeloma cells. The cell suspension is spun down at 800 rpm for 8 min and the supernatant poured off. The cells are resuspended in 2 mL/spleen 50% aqueous polyethylene glycol solution added over a 3-min period with gentle swirling, then 1 mL/spleen DMEM is added over a 1.5 min period, and 5 mL/spleen Super DMEM is added over an additional 1.5 min period. The cells are spun down at 800 rpm for 8 min, the supernatant poured off, and the cells resuspended in HAT media, approximately 100 mL/spleen. The fusing cells are then plated out into four to six 96-well plates per spleen and placed in a CO₂ incubator. The plates are fed with HAT media on Day 7, with HT media on Day 10 and are screened on Day 12.

[0246] All cells are cloned and grown in macrophage-conditioned media. This media is made by injecting 10 mL of Super DMEM into the peritoneal cavity of an euthanized mouse. Macrophage cells are loosened by tapping the outside of the cavity, and the media is withdrawn and added to 200 mL of Super DMEM. The cells are allowed to grow in a CO₂ incubator for 3-4 days, then the media is filtered through a 0.22 µm filter to remove all cells. The supernatant is mixed with 350 mL of additional Super DMEM. This resultant

"macrophage-conditioned" media is stored at 4 °C. It should be used within one month. Cloned lines are frozen down and stored at -100 °C in 10% DMSO (in Super DMEM).

[0247] Monoclonal antibody subclasses are determined using a variety of mouse monoclonal antibody isotyping kits, most frequently those by Southern Biotechnology and Zymed. All are ELISA based, and culture supernatant and manufacturer's instructions were followed.

B. Primary Screening

[0248] The primary fusion screen is a reverse ELISA procedure which was set up such that the monoclonal antibody is bound on the Enzyme Immunoassay (EIA) plate by rabbit anti-mouse Ig serum, and positive wells are selected by their ability to bind enzyme conjugates of the specific drug in question. The fusion is initially screened with the Met-Sensitive (H12)/G6PDH Enzyme conjugate described in Example 24 C. Positives from this primary screens are transferred to 24-well plates, allowed to grow for several days, then are screened by a competition reverse ELISA, wherein the enzyme conjugate must compete with free drug *i.e.*, lopinavir, for antibody binding sites. If the enzyme activity measured when free drug is present is less than that seen when only enzyme conjugate is present, then the antibody preferentially binds the free drug over the enzyme conjugated form. Screening duplicate plates involving several different free drug solutions gives an indication of relative preference for each of the drugs. Selected wells from the competition screen are cloned by serial dilution at least four times, and cloning plates can be screened by reverse ELISA; occasional competition reverse ELISAs are used to eliminate more monoclonal antibodies during the cloning process.

C. Secondary Screening

[0249] Positives from the primary screen are also tested on a Cobas Mira analyzer for inhibition of enzyme conjugate and cross-reactivity with various free drug solutions in the homogeneous enzyme immunoassay configuration. Selected monoclonal antibodies are again tested for modulation and cross-reactivity and eliminated from consideration.

D. Selected Antibody Scale-Up

[0250] Clones that are selected as acceptable according to primary and second antibody screening are used in scaling up antibody production. This scale up is performed in ascites. The mice are primed by an ip injection of FIA to induce tumor growth, 0.3 to 0.5 mL/mouse, 2 to 7 days prior to passage of cells. Cells are grown up in log phase in a T-75 flask, about 18 x

10⁶ cells, centrifuged, and then resuspended in 2 mL of S-DMEM. Each mouse can receive a 0.5 mL ip injection of approximately 4-5 x 10⁶ cells. An ascites tumor usually develops within a week or two. The ascites fluid containing a high concentration of antibody are then drained using an 18-gauge needle. The fluid are allowed to clot at room temperature and then
5 centrifuged at 1500 rpm for 30 min. The antibody containing fluid are then poured off and stored frozen at -20 °C.

EXAMPLE 28

Preparation of Polyclonal Antibodies reactive to Met-Sensitive Moiety (H12)

[0251] This technique is generally applicable to produce polyclonal antibodies to the met-sensitive moieties and NNRTI derivatives of the invention.
10

[0252] Polyclonal sera from a live rabbit are prepared by injecting the animal with an immunogenic formulation. This immunogenic formulation comprises 200 µg of the immunogen for the first immunization and 100 µg for all subsequent immunizations. Regardless of immunogen amount, the formulation is then diluted to 1 mL with sterile saline
15 solution. This solution is then mixed thoroughly with 1 mL of the appropriate adjuvant: Freund's Complete Adjuvant for first immunization or Freund's Incomplete Adjuvant for subsequent immunizations. The stable emulsion can be subsequently injected subcutaneously with a 19 x 1 1/2 needle into New Zealand white rabbits. Injections can be made at 3-4 week intervals. Bleeds of the immunized rabbits are taken from the central ear artery using a 19 x 1
20 needle. Blood can be left to clot at 37 °C overnight, at which point the serum was poured off and centrifuged. Finally, preservatives are added in order to form the polyclonal antibody material. Rabbit polyclonal antibodies to tipranavir Met-Sensitive Moiety (H11) produced by the above procedure are designated **Anti-(H11)1** and **Anti-(H11)2**, and polyclonal antibodies to tipranavir Met-Sensitive Moiety (H12) are designated **Anti-(H12)1** and **Anti-(H12)2**.

EXAMPLE 29

Selection of Enzyme Conjugates and Antibodies

[0253] This technique is generally applicable to select for enzyme conjugates comprising the met-sensitive moieties and NNRTI derivatives of the invention. This technique is also generally applicable to select for antibodies raised against the met-sensitive moieties and
30 NNRTI derivatives of the invention.

[0254] Enzyme Conjugates comprising Met-Sensitive Moiety **(H12)** and G6PDH ("Enzyme Conjugate **(H12)**/G6PDH"), as well as Met-Sensitive Moiety **(H11)** and G6PDH ("Enzyme Conjugate **(H11)**/G6PDH") are prepared according to Example 23. The binding of **(H12)** to G6DPH can reduce the activity of the enzyme, and thus its Max Inhibition level, over the pre-conjugate activity level. The binding for **(H11)** to G6PDH reduces the enzyme activity of the enzyme, and thus its Max Inhibition level, over the pre-conjugate activity level. The Enzyme Conjugates are each included in a reagent mixture ("Enzyme Conjugate **(H11)**/G6PDH Reagent" and "Enzyme Conjugate **(H12)**/G6PDH Reagent"). These mixtures contain the enzyme conjugate, HEPES buffer, bulking agents, stabilizers, and preservatives.

[0255] G6PDH activity in the Enzyme Conjugates are optimized to give an enzymatic reaction rate (OD_{max}) of 550 mA/min. The optimized activity is referred to as OD_{max} . OD_{max} represents the maximum optical density (signal) which the signal producing system can generate under the assay conditions. OD_{max} is determined by measuring the optical density produced by combining the specified amount of each conjugate with the specified amounts of the other components of the signal producing system in the absence of antibody.

[0256] Antibodies evaluated for percent inhibition against this enzyme conjugate included **Anti-(H11)1**, **Anti-(H11)2**, **Anti-(H12)1**, and **Anti-(H12)2** of Example 28. Key selection factors included maximum inhibition of enzyme conjugate and reduction in inhibition by addition of tipranavir.

**Table 3. Max Inhibition of G6PDH in Immunogen
When Combined With Antibody**

	Percent Anti-Fragment Antibody Max Inhibition			
	Anti-(H12)1	Anti-(H12)2	Anti-(H11)1	Anti-(H11)2
Enzyme Conjugate (H11)	38.2	41.5	52.9	54.9
Enzyme Conjugate (H12)	65.6	62.7	67.2	59.0

EXAMPLE 30

Immunoassay for Tipranavir in Serum Samples

A. Materials and Methods

[0257] This technique is generally applicable to select for immunoassays involving the met-sensitive moieties and NNRTI derivatives of the invention.

[0258] Enzyme Conjugate **(H12)**/G6PDH and Antibody **Anti-(H12)2** were selected as exemplary materials for the development of a homogeneous enzyme immunoassay for the

anti-HIV therapeutic tipranavir. Enzyme Conjugate **(H12)**/G6PDH Reagent, as described in Example 28, was used. Also antibody **Anti-(H12)2** was used in this Example as part of an antibody reagent ("**Anti-(H12)2** Antibody Reagent") further comprising nicotinamide adenine dinucleotide, glucose-6-phosphate, sodium chloride, bulking agent, surfactant, and preservatives.

[0259] An immunoassay for tipranavir was conducted on the Cobas Mira Chemistry Analyzer (Roche). On the analyzer, 4 μ L of sample plus 61 μ L water were incubated for 300 sec with 150 μ L of **Anti-(H12)2** Antibody Reagent. Subsequently, 75 μ L of the Enzyme Conjugate **(H12)**/G6PDH Reagent was added. After 25 sec incubation, enzyme activity was monitored by following the production of NADH spectrophotometrically at 340 nm for 50 sec.

B. Assay Performance

B. i) Standard Curve

[0260] A series of known concentrations of tipranavir standards (ranging from 0 to 10 μ g/mL) were prepared gravimetrically in MES (2-(N-Morpholino)ethanesulfonic acid, 0.01 M, pH 5.5) formulated with EDTA, protein additive, detergent, antiform agent, and preservative. Similarly, quality control samples were prepared (1.0 and 5.0 μ g/mL).

[0261] Tipranavir was dissolved in methanol to give a stock solution of 1000 μ g/mL. Synthetic buffered calibrator matrix 10 mL aliquots were spiked to give tipranavir standards with concentrations shown in Table 4. A series of **Anti-(H12)2** Antibody Reagents were prepared by adding antibody to antibody/substrate diluent. Each antibody/substrate reagent was assayed with Enzyme Conjugate **(H12)**/G6PDH Reagent. Calibration curves were generated on the Cobas Mira by assaying each level in duplicate. An example of these calibration curves is provided in **FIG. 1**.

Table 4

Tipranavir Concentration (μ g/mL)	Reaction Rate (mA/min) Average of Duplicates
0.00	344.7
5.00	400.0
10.00	434.0
25.00	487.6

50.00	532.3
0.00	344.7

B. ii) Within-run precision

[0262] Human serum samples spiked with known concentrations of tipranavir were used to assess within-run precision. A stock solution of tipranavir was prepared by dissolving tipranavir in methanol to give a stock solution of 1000 µg/mL. Negative HIV therapeutic pooled human serum was spiked to give a final nominal concentration of 1.0 and 5.0 µg/mL. Determinations were performed by assaying 20 replicates at each of two levels. Quantification was performed on the Cobas Mira analyzer.

Table 5. Within-run Precision

N	Spiked Level (µg/mL)	Mean (µg/mL)	SD	CV (%)
20	2.5	2.36	0.27	11.31
20	7.5	7.71	0.41	5.33
20	20.0	19.54	0.94	4.80
20	35.0	32.20	1.99	6.17

B. iii) Analytical Recovery

[0263] The human serum samples spiked with known concentrations of tipranavir, as described in part B. ii) above, were also used to assess analytical recovery. A stock solution of tipranavir was prepared by dissolving tipranavir in methanol to give a stock solution of 1000 µg/mL. Ten individual HIV drug negative human serum samples were split into two 1 mL sample sets. One set of ten samples was spiked to give a nominal concentration of 1 and the other set of 10 samples spiked to give a nominal concentration of 5 µg/mL. Each sample was assayed in duplicate on the Cobas Mira analyzer. Averaged data is provided in Table 6.

Table 6. Analytical Recovery Data Summary

Spiked Level ($\mu\text{g/mL}$)	Mean ($\mu\text{g/mL}$)	Recovery (%)
1.0	1.01	101.3
5.0	4.78	95.6

B. iv) Specificity of the Immunoassay

[0264] The specificity of the immunoassay was evaluated by adding potentially crossreactant drugs to human serum and determining the increase in the apparent concentration as a result of the presence of crossreactant. Separate stock solutions of tipranavir, ritonavir, amprenavir, saquinavir, indinavir, nelfinavir, efavirenz, lopinavir and lamivudine were prepared by dissolving the drug in methanol to give a stock solution of 1000 $\mu\text{g/mL}$. 10 $\mu\text{g/mL}$ of crossreactant plus 5 $\mu\text{g/mL}$ of tipranavir was added to individual human serum samples to give a final volume of 1 mL. Each sample was assayed in duplicate. Testing was performed on the Cobas Mira analyzer. The percentage concentration above 5 $\mu\text{g/mL}$ of tipranavir was calculated for each crossreactant.

Table 7. Tipranavir Cross-Reactivity of Antibody with other PIs and NNRTIs used in anti-HIV therapy


Sample	Percent Increase in Apparent Tipranavir
Ritonavir 10 $\mu\text{g/mL}$	0%
Amprenavir 10 $\mu\text{g/mL}$	0%
Saquinavir 10 $\mu\text{g/mL}$	0%
Indinavir 10 $\mu\text{g/mL}$	0%
Nelfinavir 10 $\mu\text{g/mL}$	0%
Efavirenz 10 $\mu\text{g/mL}$	0%
Lopinavir 10 $\mu\text{g/mL}$	0%
Lamivudine	0%

[0265] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent

applications cited herein are hereby incorporated by reference in their entirety for all purposes.

WHAT IS CLAIMED IS:

1 **1.** A compound having the structure:



3 wherein I is a met-sensitive moiety of an anti-HIV therapeutic, wherein said
4 anti-HIV therapeutic is selected from the group consisting of a HIV
5 protease inhibitor (PI), a nucleoside HIV reverse transcriptase inhibitor
6 (NRTI) and an HIV entry inhibitor (EI);

7 X is selected from the group consisting of O, NH, and CH₂;

8 Y is selected from the group consisting of O, NH, CH₂, and CH₂-S;

9 k, m, n, and p are independently selected from 0 and 1;

10 L is a linker consisting of from 1 to 40 carbon atoms arranged in a straight
11 chain or a branched chain, saturated or unsaturated, and containing up to
12 two ring structures and 0-20 heteroatoms, with the provision that not more
13 than two heteroatoms may be linked in sequence; and











14 Q is a reactive functional moiety chosen from the group consisting of active
15 esters, halogens, isocyanates, isothiocyanates, thiols, imidoesters,
16 anhydrides, maleimides, thiolactones, diazonium groups and aldehydes.


1 **2.** The method of claim 1, wherein said PI is a member selected from
2 tipranavir, darunavir and tenofovir.

1 **3.** The method of claim 1, wherein said NRTI is lamuvidine.


1 **4.** The method of claim 1, wherein said EI is maraviroc.

5. The compound of claim 1, wherein said I is a member selected from:






(N1);




(N2); and




(N3).


6. The compound of claim 1, wherein k is 1, X is O, m is 0, n is 0, p is 0, Q is succinimide, and I is a member selected from:




(H3),




(H4),




(H5),




(H6),




(H7),




(H8);




(K1),



(K2),



7. A compound having the structure:



wherein I is a met-sensitive moiety of an anti-HIV therapeutic, wherein said anti-HIV therapeutic is selected from the group consisting of a HIV protease inhibitor (PI), a nucleoside HIV reverse transcriptase inhibitor (NRTI) and an HIV entry inhibitor (EI);

X is selected from the group consisting of O, NH, and CH₂;

Y is selected from the group consisting of O, NH, CH₂, and CH₂-S;

k, m, n, and p are independently selected from 0 and 1;

L is a linker consisting of from 1 to 40 carbon atoms arranged in a straight chain or a branched chain, saturated or unsaturated, and containing up to two ring structures and 0-20 heteroatoms, with the provision that not more than two heteroatoms may be linked in sequence;

Z is a moiety selected from the group consisting of -CONH-, -NHCO-, -NHCONH-, -NHCSNH-, -OCONH-, -NHOCO-, -S-, -NH(C=NH)-, -N=N-, and -NH-;

P is a member selected from a polypeptide, a polysaccharide, a synthetic polymer, a carrier protein, an enzyme, a fluorogenic compound, and a chemiluminescent compound; and


r is a number from 1 to the number of hapten binding sites on P.

8. The method of claim 7, wherein said PI is a member selected from tipranavir, darunavir and tenofovir.


9. The method of claim 7, wherein said NRTI is lamuvidine.

10. The method of claim 7, wherein said EI is maraviroc.


11. The compound of claim 7, wherein said I is a member selected from:




(H3),




(H4),




(H5),




(H6),




(H7),




(H8);




(K1),




(K2),




(K3);




(K4);



(N1);



(N2); and



(N3).

12. An antigen for generating an antibody specific for a met-sensitive moiety of an anti-HIV therapeutic.

13. A receptor that specifically binds to the compound of claim 1.

14. The receptor of claim 13, wherein said receptor is selected from a Fab, Fab', F(ab')₂, Fv fragment, and a single-chain antibody.

15. The receptor of claim 13, wherein said receptor is specific for a met-sensitive moiety of amprenavir and has less than 10% cross-reactivity with atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, and tipranavir.

16. A receptor of claim 1, wherein I is a member selected from (H3), (H4), (H5), (H6), (H7) and (H8), and the receptor is a monoclonal antibody.

1 **17.** A receptor that substantially competes with the binding of the
2 monoclonal antibody of claim **16** and the compound of claim **1**, wherein I is a member
3 selected from **(H3)**, **(H4)**, **(H5)**, **(H6)**, **(H7)** and **(H8)**.

1 **18.** A receptor that substantially competes with the binding of the receptor
2 of claim **15** and the compound of claim **1**, wherein I is a member selected from **(H3)**, **(H4)**,
3 **(H5)**, **(H6)**, **(H7)** and **(H8)**.

1 **19.** The receptor of claim **18**, wherein said receptor further comprises an
2 antigen-binding domain.

1 **20.** A receptor that specifically binds to the compound of claim **7**.

1 **21.** The receptor of claim **20**, wherein said receptor is selected from a Fab,
2 Fab', F(ab')₂, Fv fragment, and a single-chain antibody.

1 **22.** The receptor of claim **20**, wherein said receptor is specific for a met-
2 sensitive moiety of amprenavir and has less than 10% cross-reactivity with atazanavir,
3 indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, and tipranavir.

1 **23.** A receptor of claim **1**, wherein I is a member selected from **(H3)**, **(H4)**,
2 **(H5)**, **(H6)**, **(H7)** and **(H8)**, and the receptor is a monoclonal antibody.

1 **24.** A receptor that substantially competes with the binding of the
2 monoclonal antibody of claim **23** and the compound of claim **1**, wherein I is a member
3 selected from **(H3)**, **(H4)**, **(H5)**, **(H6)**, **(H7)** and **(H8)**.

1 **25.** A receptor that substantially competes with the binding of the receptor
2 of claim **22** and the compound of claim **7**, wherein I is a member selected from **(H3)**, **(H4)**,
3 **(H5)**, **(H6)**, **(H7)** and **(H8)**.

1 **26.** The receptor of claim **25**, wherein said receptor further comprises an
2 antigen-binding domain.

Figure 1